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INTRODUCTION
Over the past three decades, orally disintegrating tablets (ODTs) have gained much
attention as a preferred alternative to conventional oral dosage forms such as tablets and
capsules. An ODT is a solid dosage form that disintegrates and dissolves in the mouth (either or
beneath the tongue or in the buccal cavity) without water within 60 seconds or less [1]. The US
Food and Drug Administration Center for Drug Evaluation and Research (CDER) defines in
the Orange Book an ODT as "A solid dosage form containing medicinal substances, which
disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue [2]. The
European Pharmacopoeia however defines a similar term; orally disperse, as a tablet that can be
placed in the mouth where it disperses rapidly before swallowing [3].
These tablets are distinguished from conventional sublingual tablets, lozenges, and buccal
tablets which require more than a minute to dissolve in the mouth. In the literature, ODTs also
are called orally disintegrating, orally disperse, mouth-dissolving, quick-dissolve, fast-melt, and
rapid-disintegrating tablets and freeze-dried wafers [4].
Orally disintegration tablet release drug in the mouth for absorption through local
oromucosal tissues and through pre-gastric (e.g., oral cavity, pharynx, and esophagus), gastric
(i.e., stomach), and post-gastric (e.g., small and large intestines) segments of the gastrointestinal
tract [5]. In this article, the term conventional oral dosage forms refers to tablets and capsules that
must be swallowed with water for dissolution, release, and absorption of the drug in the stomach
and GIT distal sites [6].
For the past one decade, there has been an enhanced demand for more patient-friendly
and compliant dosage forms [7]. As a result, the demand for developing new technologies has
been increasing annually. Since the development cost of a new drug molecule is very high,
efforts are now being made by pharmaceutical companies to focus on the development of new
drug dosage forms for existing drugs with improved safety and efficacy together with reduced
dosing frequency, and the production of more cost effective dosage forms [8].
For most therapeutic agents used to produce systemic effects, the oral route still
represents the preferred way of administration, owing to its several advantages and high patient
compliance compared to many other routes [9]. Tablets and hard gelatin capsules constitute a
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major portion of drug delivery systems that are currently available. However, many patient
groups such as the elderly, children, and patients who are mentally retarded, uncooperative,
nauseated, or on reduced liquid-intake/diets have difficulties swallowing these dosage forms.
Those who are traveling or have little access to water are similarly affected [10].
To fulfill these medical needs, pharmaceutical technologists have developed a novel oral
dosage form known as Orally Disintegrating Tablets (ODTs) which disintegrate rapidly in saliva,
usually in a matter of seconds, without the need to take it water [11]. Drug dissolution and
absorption as well as onset of clinical effect and drug bioavailability may be significantly greater
than those observed from conventional dosage forms [12]. Although chewable tablets have been
on the market for some time, they are not the same as the new ODTs. Patients for whom chewing
is difficult or painful can use these new tablets easily. ODTs can be used easily in children who
have lost their primary teeth but do not have full use of their permanent teeth [13].
Recent market studies indicate that more than half of the patient population prefers ODTs
to other dosage forms and most consumers would ask their doctors for ODTs (70%), purchase
ODTs (70%), or prefer ODTs to regular tablets or liquids (>80%) [14].
Orally disintegration tablet products have been developed for numerous indications
ranging from migraines (for which rapid onset of action is important) to mental illness (for which
patient compliance is important for treating chronic indications such as depression and
schizophrenia) [15].
A freeze-dried wafer:
Is a quick-dissolving, thin matrix that contains a medicinal agent that does not need water
for swallowing. This fragile dosage form requires unit-dose packaging to ensure physical
stability. The wafer disintegrates instantaneously in the oral cavity and releases drug, which
dissolves or disperses in the saliva. [16] The saliva is swallowed and the drug is absorbed across
the gastrointestinal tract (GIT). An orally disintegrating tablet (ODT) is a solid dosage form that
contains medicinal substances and disintegrates rapidly (within seconds) without water when
placed on the tongue. The drug is released, dissolved, or dispersed in the saliva, and then
swallowed and absorbed across the GIT1 [17].
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A quick-dissolving tablet:
A quick-dissolving tablet (also known as a fast-dissolving, fast-dissolving
multiparticulate, rapid-dissolving, mouth-dissolving, fast melting, or orodispersing tablets) is an
oral tablet that does not require water for swallowing. The tablet dissolves within 60 seconds
when placed in the mouth [18]. The active ingredients are absorbed through mucous membranes
in the mouth and GIT and enter the blood stream. A fraction of pre-gastric drug absorption may
bypass the digestive system and metabolism by the stomach acids and enzymes. In general, the
tablets are physically robust and can be packaged in multi dose containers [1, 19].
WHO Guidelines:
This guidance represents the Food and Drug Administration's (FDA's) current thinking on
this topic. It does not create or confer any rights for or on any person and does not operate to
bind FDA or the public. You can use an alternative approach if the approach satisfies the
requirements of the applicable statutes and regulations. If you want to discuss an alternative
approach, contact the FDA staff responsible for implementing this guidance. If you cannot
identify the appropriate FDA staff, call the appropriate number listed on the title page of this
guidance.
This guidance provides pharmaceutical manufacturers of new and generic drug products
with an Agency perspective on the definition of an orally disintegrating tablet (ODT)—which is
a different dosage form than, for example, a chewable tablet or a tablet that should be swallowed
whole with liquid—and also provides recommendations to applicants who would like to
designate proposed products as ODTs.
FDA's guidance documents, including this guidance, do not establish legally enforceable
responsibilities. Instead, guidance describes the Agency's current thinking on a topic and should
be viewed only as recommendations, unless specific regulatory or statutory requirements are
cited. The use of the word should in Agency guidance means that something is suggested or
recommended, but not required [20].
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Ideal properties of ODTS:
The performance of ODTs depends on the technology used during their manufacture. The
necessary property of such tablets is the ability to disintegrate rapidly and disperse or dissolve in
saliva, thereby obviating the need for water. Various technologies have been developed that
enable ODT to perform this unique function [21].
An ideal ODT should meet the following criteria:
• Does not require water for oral administration yet disintegrates and dissolves in oral
cavity within a few seconds
• Has sufficient strength to withstand the rigors of the manufacturing process and post-
manufacturing handling
• Allow high drug loading
• Has a pleasant mouth feel
• Is insensitive to environmental conditions such as humidity and temperature
• Is adaptable and amenable to existing processing and packaging machineries
• Is cost-effective [22].
The Need for Development of ODTS:
The need for non-invasive delivery systems persists due to patients poor acceptance of,
and compliance with, existing delivery regimes, limited market size for drug companies and drug
uses, coupled with high cost of disease management.
Challenge in formulating ODTS:
Palatability:
As most drugs are unpalatable, orally disintegrating drug delivery systems usually
contain the medicament in a taste-masked form. Delivery systems disintegrate or dissolve in
patients oral cavity, thus releasing the active ingredients which come in contact with the taste
buds; hence, taste-masking of the drugs becomes critical to patient compliance [23].
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Mechanical strength:
In order to allow ODTs to disintegrate in the oral cavity, they are made of either very
porous and soft-molded matrices or compressed into tablets with very low compression force,
which makes the tablets friable and/or brittle, difficult to handle, and often requiring specialized
peel-off blister packing that may add to the cost. Only few technologies can produce tablets that
are sufficiently hard and durable to allow them to be packaged in multi dose bottles, such as
Wowtab® by Yamanou [24].
Several orally disintegrating dosage forms are hygroscopic and cannot maintain physical
integrity under normal conditions of temperature and humidity. Hence, they need protection from
humidity which calls for specialized product packaging [25].
Amount of drug:
The application of technologies used for ODTs is limited by the amount of drug that can
be incorporated into each unit dose. For lyophilized dosage forms, the drug dose must be lower
than 400 mg for insoluble drugs and less than 60 mg for soluble drugs. This parameter is
particularly challenging when formulating a fast-dissolving oral films or wafers.
Aqueous solubility:
Water-soluble drugs pose various formulation challenges because they form eutectic
mixtures, which result in freezing-point depression and the formation of a glassy solid that may
collapse upon drying because of loss of supporting structure during the sublimation process.
Such collapse sometimes can be prevented by using various matrix-forming excipients such as
mannitol than can induce crystallinity and hence, impart rigidity to the amorphous composite [26].
Size of tablet:
The degree of ease when taking a tablet depends on its size. It has been reported that the
easiest size of tablet to swallow is 7-8 mm while the easiest size to handle was one larger than 8
mm. Therefore, the tablet size that is both easy to take and easy to handle is difficult to achieve
[27].
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Selection of ODT Drug Candidates:
Several factors must be considered when selecting drug candidates for delivery as ODT
dosage forms. In general, an ODT is formulated as a bioequivalent line extension of an existing
oral dosage form. Under this circumstance, it is assumed that the absorption of a drug molecule
from the ODT occurs in the post-gastric GIT segments, similar to the conventional oral dosage
form. But this scenario may not always be the case. For example, ODT formulations of
selegiline, apomorphine, and buspirone have significantly different pharmacokinetic profiles
compared with the same dose administered in a conventional dosage form [28].
It is possible that these differences may, in part, be attributed to the drug molecule,
formulation, or a combination of both. If significantly higher plasma levels have been observed,
pre-gastric absorption leading to the avoidance of first-pass metabolism may play an important
role. This situation may have implications for drug safety and efficacy, which may need to be
addressed and assessed in a marketing application for an ODT. For example, safety profiles may
be improved for drugs that produce a significant amount of toxic metabolites mediated by first
pass liver metabolism and gastric metabolism and for drugs that have a substantial fraction of
absorption in the oral cavity and segments of the pre-gastric GIT [29].
Drugs having ability to diffuse and partition into the epithelium of the upper GIT (log P >
1, or preferable > 2) and those able to permeate oral mucosal tissue are considered ideal for ODT
formulations. Patients who concurrently take anticholinergic medications may not be the best
candidates for these drugs.
Similarly, patients with Sjögrens syndrome or dryness of the mouth due to decreased
saliva production may not be good candidates for these tablet formulations. Drugs with a short
half-life and frequent dosing, drugs which are very bitter or otherwise unacceptable taste because
taste masking cannot be achieved or those which require controlled or sustained release are
unsuitable candidates of rapidly dissolving oral dosage forms.
Researchers have formulated ODT for various categories of drugs used for therapy in
which rapid peak plasma concentration is required to achieve the desired pharmacological
response. These include neuroleptics, cardiovascular agents, analgesics, antiallergic, anti-
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epileptics, anxiolytics, sedatives, hypnotics, diuretics, anti-parkinsonism agents, anti-bacterial
agents and drugs used for erectile dysfunction [30].
Approaches to ODT development:
The fast disintegrating property of the tablet is attributable to a quick ingress of water
into the tablet matrix resulting in its rapid disintegration. Hence, the basic approaches to develop
rapidly dissolving oral dosage forms include maximizing the porous structure of the tablet
matrix, incorporating the appropriate disintegrating agent and using highly water soluble
excipents in the formulation. As is often the case, a technology that is originally developed to
address a particular administration need can quickly become adopted as part of a pharmaceutical
companys product life cycle management strategy, which is precisely what has happened with
ODT technologies.   The technologies that have been used by various researchers to prepare
orally disintegrating dosage forms include: Freeze Drying or Lyophilization, Molding, Direct
Compression, Disintegrant addition, Sublimation, Spray Drying, Mass Extrusion, Cotton-candy
process, Nano Crystal  TM Technology, Oral films/wafers. Specific properties of the various
ODT technologies are listed [31, 32].
Types of dosage forms:
Dosage forms are the means (or the forms) by which drug molecules is delivery to site of
actions within the body. The need for dosage forms:
• Accurate dose.
• Protections. E.g. coated tablet, sealed ampoules.
• Protections of gastric juice.
• Masking taste and odor.
• Placement of drug within body tissues.
• Sustained release medications.
• Controlled release medications.
• Optimal drug action
• Insertion of drug in to body cavities.
• Use of desired vehicle for insoluble drugs.
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Route of administration:
A route of administration in pharmacology in toxicology is the path by which a drug,
fluid, poison, or other substance is taken in to the body. Route of administration are generally
classified by the location which the substance is applied. Common examples include oral and
intravenous administration.
Type of administrations:
• Oral route .many drugs of administered orally as liquids, capsules, tablets,
• Parenteral route.
• Inhalation.
• Topical
Tablet:
Tablet may be defined as the solid unit dosage form of medicament or medicaments with
or without suitable excipients and prepared either molding or by compression. It comprises a
mixture of active substance and excipients, usually in powder form, pressed or compacted form a
powder in to a solid dose.
Types of tablets:
(A)Tablet ingested orally:
• Compressed tablet  e.g. paracetamol tablet
• Multiple compressed tablet
• Repeat action tablet
• Delayed release tablet  e.g. enteric coated tablet
• Sugar coated tablet e.g. multivitamin tablet.
• Film coated tablet e.g. Metronidazole
• Orally disintegrating tablet e.g. ondonsetron
• Chewable tablet  e.g. antacid tablet
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(B) Tablet used in buccal cavity:
• Buccal tablet e.g. vitamin-c tablet
• Sublingual tablet e.g. nitro glycerin
• Troches or lozenges
• Dental cone
(C) Tablet administered by other route:
• Implantation tablet
• Vaginal tablet
(D)Tablet used to prepare solution:
• Effervescent tablet e.g. dispirin tablet (aspirin)
• Dispensing tablet e.g. enzyme tablet
• Hypodermic tablet (digiplex) ([33].
Orally disintegrating tablet
Orally disintegrating tablets (ODTs) were defined as a solid dosage form containing
medicinal substances that disintegrate within a matter of seconds when placed on tongue.
According to European Pharmacopeia, ODTs were defined as orodisperse that can be placed in
mouth where it disperses rapidly before swallowing. These are appropriate dosage form for older
people, children, and bedridden patients because it can be difficult for these patients to swallow
conventional tablets or capsules. In these patients, medication compliance and therapeutic effect
could be improved by taking ODTs that can rapidly and easily disintegrate in oral cavity[34].
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Figure no. 1 orally disintegration tablet
Advantages of ODT:
• Ease of administration to patients who refuse to swallow a tablet, such as pediatric,
geriatric, mentally ill, disabled and uncooperative patients.
• Rapid dissolution of drug and absorption may produce rapid onset of action.
• Pregastric absorption can result in improved bioavailability, and as a result of reduced
dosage, improved clinical performance by reducing side effects.
• No need of water to swallow the dosage form, which is highly convenient feature for
patients who are travelling and do not have immediate access to water.
• Convenience of administration and accurate dose as compared to liquids.
• Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva passes
down into the stomach; in such cases bioavailability of drugs is increases.
• Good mouth feel property of ODTS helps to change the psychology of medication as
“bitter pill” particularly in pediatrics patients.
• Ability to provide advantages of liquid medication in the form of solid preparation.
• New business opportunities product differentiation, line extension and lifecycle
management, exclusivity of the product promotion and patent-life extension.
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Disadvantages of ODT:
• Rapid disintegrating tablets are hygroscopic in nature so must be kept at controlled
environment i.e. Humidity and temperature.
• For properly stabilization and safety of stable product, ODT requires special packaging.
• Usually have insufficient mechanical strength. Hence, careful handling is required.
• Leave unpleasant taste and/or grittiness in mouth if not formulated properly [35].
Need for ODTs:
• Orally disintegrating dosage forms are particularly suitable for patients find it
inconvenient to swallow traditional tablets and capsules with glass of water.
• Pediatric and geriatric patients
• Patients who are unwilling to take solid preparation due to fear of choking
• A patient with persistent nausea, who may be in journey, or has little or no access to
water
• Increased bioavailability and faster onset of action are a major claim of these
formulations [36].
Figure no. 2 Breakdown of ODT
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Figure no. 3 Mechanism of drug release
Figure no. 4 Disintegration of drug particles
Main ingredients used in preparation of ODT:
Important ingredients that are used in the formulation of ODT should allow quick release
of the drug, resulting in faster dissolution. This includes both the active and the excipients.
Disintegration and solubilization of a directly compressed tablet depend on single or combined
effects of disintegrate, water soluble excipients and effervescent agents [37].
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Regulatory definitions:
US Definition:
• Orally disintegrating tablet
• A solid dosage form containing medicinal substances which disintegrates rapidly, usually
within a matter of seconds when placed upon the tongue
• Tablet weight <500mg. In-vitro USP disintegration test <30 seconds.
• FDA guidance for industry -orally disintegrating tablets
EU Definition:
• Orodispersible tablets
• Orodispersible tablets are uncoated tablets intended to be placed in the mouth where they
disperse rapidly before being swallowed
• Disintegration Test: Orodispersible tablets disintegrate within 3 mins when examined by
the test for disintegration.
• European Pharmacopoeia [38].
Figure no. 5 Disintegration of ODT
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Mechanism of tablet disintegration:
• Swelling
• Porosity and Capillary action
• Deformation
• Due to disintegrating particle/particle repulsive forces
Swelling:
Although not all effective disintegrant swell in contact with water, swelling is believed to
be a mechanism in which certain disintegrating agents (such as starch) impart the disintegrating
effect. By swelling in contact with water, the adhesiveness of other ingredients in a tablet is
overcome causing the tablet to fall apart.
Porosity and Capillary Action (Wicking):
Effective disintegrant that do not swell are believed to impart their disintegrating action
through porosity and capillary action. Tablet porosity provides pathways for the penetration of
fluid into tablets. The disintegrant particles (with low cohesiveness & compressibility)
themselves act to enhance porosity and provide these pathways into the tablet. Liquid is drawn
up or “wicked” into these pathways through capillary action and rupture the inter-particulate
bonds causing the tablet to break apart.
Due to disintegrating particle/particle repulsive forces:
Another mechanism of disintegration attempts to explain the swelling of tablet made with
non swellable disintegrants. Guyot-Hermann has proposed a particle repulsion theory based on
the observation that non swelling particle also cause disintegration of tablets. The electric
repulsive forces between particles are the mechanism of disintegration and water is required for
it. Researchers found that repulsion is secondary to wicking. In recent years, several newer
agents have been developed known as “Super disintegrants”. These newer substances are more
effective at lower concentrations with greater disintegrating efficiency and mechanical strength.
On contact with water the super disintegrants swell, hydrate, change volume or form and produce
a disruptive change in the tablet. Effective super disintegrants provide improved compressibility,
compatibility and have no negative impact on the mechanical strength of formulations containing
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high-dose drugs. Super disintegrants offer significant improvements over starch. But
hygroscopicity may be a problem in some formulations. As days passes, demand for faster
disintegrating formulation is increased. Super disintegrants which are effective at low
concentration and have greater disintegrating efficiency and they are more effective Intra
granularly. And this super disintegrants act by swelling and due to swelling pressure exerted in
the outer direction or radial direction, it causes tablet to burst or the accelerated absorption of
water leading to an enormous increase in the volume of granules to promote disintegration.
Three major groups of compounds have been developed which swell to many times their original
size when placed in water while producing minimal viscosity effects [39].
Selection of super-disintegrates:
The ideal superdisintegrant should have:
• Poor gel formation.
• Good hydration capacity.
• Good molding and flow properties
• No tendency to form complexes with the drugs.
• Good mouth feel.
• It should also be compatible with the other excipients and have desirable tableting
properties [40].
Mechanism action of super-disintegrant:
Swelling:
Perhaps the most widely accepted general mechanism of action for tablet disintegration is
swelling. Tablets with high porosity show poor disintegration due to lack of adequate swelling
force.  On the other hand, sufficient swelling force is exerted in the tablet with low porosity. It is
worthwhile to note that if the packing fraction is very high, fluid is unable to penetrate in the
tablet and disintegration is again slows down [41].
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Figure no. 6 Swelling
Porosity and capillary action (Wicking):
Disintegration by capillary action is always the first step. When we put the tablet into
suitable aqueous medium, the medium penetrates into the tablet and replaces the air adsorbed on
the particles, which weakens the intermolecular bond and breaks the tablet into fine particles.
Water uptake by tablet depends upon hydrophilicity of the drug/excipients and on tableting
conditions. For this type of disintegrants, maintenance of porous structure and low interfacial
tension toward aqueous fluid is necessary which helps in disintegration by creating a hydrophilic
network around the drug particles [42].
Figure no.7 Wicking
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Due to disintegrating particle-particle repulsive forces:
Another mechanism of disintegration attempts to explain the swelling of tablet made with
non swellable disintegrants. Guyot-Hermann has proposed a particle repulsion theory based on
the observation that no swelling particles also cause disintegration of tablets. The electric
repulsive forces between particles are the mechanism of disintegration and water is required for
it. [43].
Figure no. 8 Particle-particle repulsive forces
Due to deformation:
During tablet compression, disintegrated particles get deformed and these deformed
particles get into their normal structure when they come in contact with aqueous media or water.
Occasionally, the swelling capacity of starch was improved when granules were extensively
deformed during compression. This increase in size of the deformed particles produces a breakup
of the tablet [44].
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Figure no.9 Deformation
Because of heat of wetting (air expansion):
When disintegrants with exothermic properties gets wetted, localized stress is generated
due to capillary air expansion, which helps in disintegration of tablet. This explanation, however,
is limited to only a few types of disintegrants and cannot describe the action of most modern
disintegrating agents [45].
Due to release of gases:
Carbon dioxide released within tablets on wetting due to interaction between bicarbonate
and carbonate with citric acid or tartaric acid. The tablet disintegrates due to generation of
pressure within the tablet. This effervescent mixture is used when pharmacist needs to formulate
very rapidly dissolving tablets or fast disintegrating tablet. As these disintegrants are highly
sensitive to small changes in humidity level and temperature, strict control of environment is
required during manufacturing of the tablets. The effervescent blend is either added immediately
prior to compression or can be added in to two fraction of formulation [46].
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By enzymatic reaction:
Here, enzymes present in the body act as disintegrants. These enzymes destroy the
binding action of binder and helps in disintegration. Actually due to swelling, pressure exerted in
the outer direction or radial direction, it causes tablet to burst or the accelerated absorption of
water leading to an enormous increase in the volume of granules to promote disintegration [47].
Table1.1 List of superdisintegrants:
S NO. Example Superdisintegrants Mechanism of action Special comments
1 Crosslinked
cellulose
Crosscarmellose
Ac-Di-Sol
Primellose
Vivasol
Swells 4-8 folds in
<10seconds.
Swelling and wicking both
Swelling is in two
dimensions.
-Direct compression or
granulation
-Starch free
2 Crosslinked
PVP
Crosspovidone Swells 7-12 folds
in <30  second
Swells in three dimensions
and high level serve as
sustain release matrix
3 Crosslinked
starch
Sodium starch
Glycolate
Swells 7-12 folds
in <30  seconds
Swells in three dimensions
and high level serve as
sustain release matrix
4 Cross linked
alginic acid
Alginic acid NF Rapid swelling
in aqueous medium
or wicking action
Promote disintegration in
both dry or wet granulation
5 Natural
super
Disintegrates
Soya
Polysaccharides
Rapid Dissolving Does not contain any starch
or sugar. Used
in nutritional products[48].
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Table no. 2 Synthetic superdisintegrant
S.NO. Synthetic
superdisintegrant
Properties
Effective concentration for
Disintegrants
1 Crospovidone 1. It is completely insoluble in
water. Rapidly disperses and
swells in water. Greatest rate of
swelling .compared to other
disintegrants
2. Available  in  grades  if needed
for improving state of dispersion
in the powder blend
3.  Swelling index - 58±1.5% v/v
It is used in the range of 1-3%
w/w
2 Croscarmellose
sodium
1.It is insoluble in water, although
it rapidly    swells to 4-8 times its
original volume  on contact with
water
2. Specific surface area - 0.81-
0.83m/g
3.   Swelling index- 65±1.7% v/v
It may be used as a tablet
disintegrant at concentration up
to5% w/w, although normally
2% w/w is used in tablets
prepared by direct compression
and 3% w/win tablets prepared
by wet-granulation process
3 Sodium starch
glycolate
1. Absorbs water rapidly, resulting
in swelling up to 6%. High
concentration causes gelling and
loss of disintegration
2.Swelling index - 52±1.2% v/v
It is used in the range of 4-6%.
Above 8%, disintegration times
may actually increase due to
gelling
and its subsequent viscosity
producing effects
4 Polacrilin
potassium
No lump formation after
disintegration
High compatibility with excipients
and   common therapeutic
Used as a tablet disintegrant and
as taste masking agent for
various drugs [49].
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Taste-masking agents:
Taste masking of drug may be achieved with preventing the exposure of drug to the
tongue through processing or adding competing taste-masking agents. Exposure of solubilized
drug to the oral cavity can be prevented by encapsulation in polymer systems or complexation.
The approaches are as follows:
• Layering the drug onto inert beads using a binder followed by coating with a
taste-masking polymer.
• Granulating the drug and coating with a taste masking polymer.
• Spray drying the drug dispersed or dissolved in a polymeric solution to get taste-
masked particles.
• Complexation by the use of inclusion in cyclodextrins.
• Psychological modulation of bitterness
• Coacervation to form microencapsulated drug within a polymer.
• Formation of pellets by extrusion spheronization [50].
Sweeteners:
Sucrose and other natural sweeteners, such as sorbitol, can be used in effervescent
products, although artificial sweetening agents are customary. However, the application of
artificial sweeteners is restricted by health regulations. Saccharin or its sodium and calcium salts
are used as sweeteners. Aspartame is also employed as a sweetener in effervescent tablets.
Earlier, cyclamates and cyclamic acid were the artificial sweeteners of choice, but their use has
now been restricted. Some commonly used sweeteners are:
Example: Sorbitol, Mannitol, Maltitol solution, Maltitol, Xylitol, Erythritol, Sucrose, Fructose,
Maltose, aspartame, Glycerin, sugars derivatives etc [51].
Binders:
Main role of Binders is to keep the composition of these fast melting tablets together
during the compression stage. Binders can either be liquid, semisolid, solid or mixtures of
varying molecular weights such as polyethylene glycol. The right selection of a binder or
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combination of binders is essential to maintain the integrity and stability of the tablet. The
temperature of the excipient should be preferably around 30–35oC for faster melting properties.
Further, its incorporation imparts smooth texture and disintegration characteristics to the system.
Example:
Binders commonly used are cellulosic polymers such as ethylcellulose, hydroxylpropyl
cellulose (HPC), and hydroxyl propylmethyl cellulose (HPMC), alone or in admixtures
povidones, polyvinyl alcohols, and acrylic polymers. Acrylic polymers used are the
ammoniomethacrylate copolymer, polyacrylate, and polymethacrylate. Among the cellulosic [52].
Antistatic agent:
An antistatic agent is a compound used for treatment of materials or their surfaces in
order to reduce or eliminate buildup of static electricity generally caused by the turboelectric
effect. An additional thickening agent, generating a stabilized suspension, is added to avoid
settling of the particles and moreover provide a pleasant mouth feeling. Example: colloidal silica
(Aerosil), precipitated silica (Sylod.FP244), micronized or non micronized talc, maltodextrins,
beta-cyclodextrins, etc. Magnesium stearate, stearic acid, sodium stearylfumarate, micronized
polyoxyethylene glycol (micronized Macrogol 6000), leucine, sodium benzoate are used as
lubricant [53].
Lubricants:
Lubricants remove grittiness and assist in the drug transport mechanism from the mouth
down into the stomach.
Example: Magnesium stearate, stearic acid, leucine, sodium benzoate, talc, magnesium lauryl
sulphate, liquid paraffin etc [54].
Flavors:
Example: Peppermint flavor, clove oil, anise oil, eucalyptus oil. Flavoring agents include,
vanilla, citrus oils, fruit essences etc. [55].
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Fillers:
Example: Directly compressible spray dried Mannitol, Sorbitol, xylitol, calcium
carbonate, magnesium carbonate, calcium phosphate, pregelatinized starch, magnesium
trisilicate, aluminium hydroxide etc. [56].
Surface active agents: Example: sodiumdoecylsulfate, sodiumlaurylsulfate, Tweens, Spans,
polyoxyethylene stearat [57].
Table no.3: Excipients profile details:
S
no.
Flavors Fillers Surface
active agents
Binder color Lubricants Sweeteners
1
Peppermint
Flavor
Directly
compressible
spray dried
Mannitol
Sodium
doecyl sulfate
Polyvinyl
pyrrolidone
(PVP)
Sunset
yellow
Stearic acid Aspartame
2
Cooling
Flavor
Sorbitol Sodium lauryl
Sulfate
Hydroxy
propylmethyl
cellulose
(HPMC)
Amaranth Magnesium
stearate
Sugars
derivative
3
Flavor oils
and
Flavoring
aromatic
oil
Xylitol Sorbitan fatty
acid esters
(spans)
Polyvinylalcohol
(PVA)
Zinc state
4
Peppermint
Oil
Magnesium
carbonate
Polyoxy
ethylene
stearates
Calcium
stat
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5
Clove oil Calcium
Bay oil
phosphate
Polyoxy
ethylene
sorbitan
fatty acid
esters(tweens)
Polyethylene
glycole
6
Bay oil Calcium
sulfate
Liquid
paraffin
7
Anise oil Pregelatinized
starch
Coilloidal
silicon
dioxide
8
Oil of
bitter
almonds
trisilicate
Magnesium
Magnesium
lauryl
sulfate
Taste masking methods:
 The drugs are mostly bitter in nature. Skillful taste masking is needed to hide the bitter
taste in ODT formulations. Following methods are used in Taste masking.
 Simple wet granulation method or rollercompaction of other excipients. Spray drying
can also employed to shroud the drug.
 Drugs can be sifted twice or thrice in small particle size mesh with excipients such as
sweeteners and flavors etc.
 Drug particles are coated directly.
 Granulation of the drug with certain excipients followed by the polymer coating.
 If the drug is tasteless or very low dose, direct blend of bulk drug substance into fast
disintegrating matrix is straightforward.
 Formation of pellets by extrusion spheronization.
 Coacervation to form microencapsulated drug within a polymer.
 Cyclodextrins can be used to trap or complex, cyclodextrin help to solubilze many drugs.
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 Drug complexation with resinates are insoluble and no taste in oral cavity. Examples of
drugs where this technique has been successfully demonstrated include ranitidine,
risperidone and paroxetine.
 Other methods include hot melt and supercritical fluids.
 Adjustment of pH Values: Many drugs are less soluble at pH different from the pH value
of the mouth, which are around 5.9. Solubilization inhibitor, such as sodium carbonate,
sodium bicarbonate, sodium hydroxide, or calcium carbonate, was added to increase the
pH when granules including a drug-sildenafil dissolved in aqueous medium, the bitter
taste of the drug were successfully masked by a sweetener alone. [58].
Table no.4 Approaches for preparation of methods:
Technologies
Conventional technologies Patented technologies
1 Freeze drying 1 Zydus technology
2 Sublimation 2 Orasolv technology
3 Spray drying 3 Durasalv technology
4 Ion exchange resin complexation 4 Wowtab technology
5 Mass extrusion 5 Flshdose  technology
6 Moulding 6 Flashtab technology
7 Direct compression 7 Oraquick technology
8 Cotton candy method 8 Pharmabust technology
9 Nanotization 9 Nanocrystal technology
10 Fast dissolving flim 10 Frosta technology
11 Melt granulation 11 Dispersible technology
Freeze drying or lyophilisation:
A process, in which water is sublimated from the product after freezing, is called freeze
drying. Freeze dried forms offer more rapid dissolution than other available solid products.
Lyophilization can be used to prepare tablets that have very porous open matrix network into
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which saliva rapidly moves to disintegrate lyophilized mass after it is placed in mouth. Apart
from the matrix and active constituents, the final formulation may contain other excipients,
which improve the process characteristics or enhance the quality of final product. These include
suspending agents, wetting agents, preservatives, antioxidants, colors and flavors. The preferred
drug characteristics for freeze drying formulations are water insoluble, low dose, chemically
stable, small particle size and tasteless.
Figure no. 10 Freeze drying or lyophilisation
Merits:
Pharmaceutical substances can be processed at non elevated temperature, thereby
eliminating adverse thermal effects.
Demerits:
(i) Due to high cost of equipments Lyophilization is relatively expensive and time consuming
manufacturing process.
(ii) Fragility, which make the use of conventional packing difficult and poor stability during
storage under stressful condition [59].
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Sublimation:
This process involves addition of some inert volatile substances like urea, urethane,
naphthalene, camphor, etc to other excipients and the compression of blend into tablet. Removal
of volatile material by sublimation creates pores in tablet structure, due to which tablet dissolves
when comes in contact with saliva. Additionally several solvents like cyclohexane, benzene etc
can also be used as pore forming agents. Orodispersable Tablets with highly porous structure and
good mechanical strength have been developed by this method [60].
Figure no.11 Sublimation
Spray drying:
A highly porous and fine powder is prepared by spray drying an aqueous
composition containing support matrix and other components. This is then mixed with active
ingredient and compressed into tablet. The formulations contained hydrolyzed and unhydrolyzed
gelatin as a supporting agent for the matrix, mannitol as a bulking agent and sodium starch
glycolate/croscaramellose as a disintegrant. Disintegration and dissolution were further
enhanced by adding an acid (e.g. citric acid) or an alkali (e.g., sodium bicarbonate). The
suspension of above excipients was spray-dried to yield a porous powder which was compressed
into tablets. Tablets manufactured by this method disintegrated in < 20 sec. in an aqueous
medium [61].
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Figure no.12 spray drying
Molding:
Molded tablets are prepared by using water soluble ingredients so that the tablets
dissolve completely and rapidly. The powder blend is moistened with a hydro-alcoholic solvent
and is molded into tablets under pressure lower than that used in conventional tablet
compression. The solvent is then removed by air drying.
Figure no. 13 Molding
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Figure no.14 molding tablet
Merits:
• Molded tablets posses porous structure, which facilitates rapid disintegration and easy
dissolution.
• Molded tablets offer improved taste due to water-soluble sugars present in dispersion
matrix.
Demerits:
• But molded tablets lack good mechanical strength and can undergo breakage or erosion
during
• Handling and opening of blister packs increase mechanical strength [62].
Heat molding:
A molten matrix in which drug is dissolved or dispersed can be directly molded into
Orodispersable Tablets. [63].
No vacuum lyophilization:
This process involves evaporation of solvent from a drug solution or suspension at a
standard pressure [64].
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Mass extrusion:
In this technique, a blend of active drug and other ingredients is softened using solvent
mixture of water soluble polyethylene glycol, using methanol and then the softened mass is
extruded through the extruder or syringe to get a cylinder of product, which is finally cut into
even segments with the help of heated blades to get tablets. The dried cylinder can be used to
coat the granules of bitter tasting drugs and there by masking their bitter taste [65].
Direct compression:
The disintegrant addition technology (direct compression) is the most preferred technique to
manufacture the tablets. Advantages:
• High doses can be accommodated and final weight of the tablet can exceed that of other
methods.
• Easiest way to manufacture the MDT tablets.
• Conventional equipment and commonly available excipients are used.
• A limited number of processing steps are involved.  Cost-effectiveness
Tablet size and hardness strongly affect the disintegrant efficacy. Hard and large tablets have
more disintegration time than normally required. Very soft and small tablets have low
mechanical strength. So, an optimum kind and concentration of disintegrant should be chosen to
achieve quick disintegration and high dissolution rates. Above the critical concentration level,
however, disintegration time remains approximately constant or even increases [66].
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Figure no.15 direct compression
Cotton-candy process:
In this process Shear form technology is used in the preparation of a matrix known as
FLOSS, made from the combination of the recipients either alone or with the drugs. The fibrous
nature of the floss is similar to the cotton-candy fibers. The floss is commonly made of
saccharides such as sucrose, dextrose, lactose and fructose at temperatures ranging between 180-
266 °F. Other polysaccharides such aspolymaltodextrins and polydextrose can be transformed
into fibers at 30-40% lower temperature range [67].
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Figure no16. Cotton-candy process
Nanonization:
In this process, the particles of the drug are reduced in size to nanoparticles by milling the
drug in the proprietary wet milling process. The agglomeration can be prevented by surface
adsorption of the nanocrystals. These are then compressed and changed into a tablet. This
technique is very useful for less water soluble drugs. The bioavailability of the drug is increased
as the disintegration time is reduced to a significant extent [68].
Fast dissolving films:
In this technique, a non-aqueous solution is prepared containing water soluble film
forming polymers (carboxy methylcellulose, hydroxypropyl methylcellulose, hydroxyl
ethylcellulose, hydroxyl propylcellulose etc.), drug and other taste masking ingredients, which is
allowed to form a film after evaporation of solvent
In case of a bitter drug, resin adsorbate or coated microparticles of the drug can be
incorporated into the film. This film, when placed in mouth, melts or dissolves rapidly, releasing
the drug in solution or suspension form [69].
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Melt granulation:
Abdelbary prepared ODT by incorporating a hydrophilic waxy binder (super polystate)
PEG6Sterate. Super polystate is a waxy material with a melting point of 33-370C. It is not only
acts as a binder and increases the physical resistance of tablets, but also helps the disintegration
of tablets as it melts in the mouth and solubilizes rapidly leaving no residue.
Advantages:
• Neither solvent nor water used in this process.
• Fewer processing steps needed thus time consuming drying steps eliminated
• Uniform dispersion of fine particle occurs.
• Good stability at varying pH and moisture levels.
Disadvantages:
• Requires high energy input
• Higher-melting-point binders require high melting temperatures and can contribute to
instability problems especially for heat-labile materials. [70].
Ion exchange resin Complexation technique:
Ion-exchange resins are vinyl, divinyl benzene and polystyrene copolymers available as
high molecular weight polyelectrolytes having extensive charged functional sites. They are
insoluble in nature and exchange their exchangeable ions with same charge ions in the
surrounding ionic medium .A part from taste masking, resins have been used in modified drug
release, drug stabilization, and tablet disintegration even in therapeutics too. Long-term
physicochemical stability and safety of ion exchange resins have provided an additional benefit
to consider them as drug carriers for a wide array of applications.
Bitter cationic drugs can get adsorbed onto the weak cation exchange resins of carboxylic
acid functionality to form the complex, which is non-bitter. The complex of cationic drugs and
weak cation exchange resin does not break at pH 6–7 of saliva with cation concentration of
40meq/l. But at high cation concentration and stomach pH of 1–3, free drug is immediately
released [71].
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General reaction of ion exchange resin complexation:
Re-So3 – Na+ + Drug+ Re-SO3 – Drug+ + Na+ ...........................................................1
Re-N (CH3) + Cl– + Drug – Re-N (CH3) + Drug – + Cl – ............................................2
Patented technologies for ODTs:
The main patented technologies for mouth dissolving tablets are as follows:
Zydis Tecnology:
Zydis formulation is a unique freeze dried tablet in which drug is physically entrapped or
dissolved within the matrix of fast-dissolving carrier material. When Zydis units are put into the
mouth, the freeze- dried structure disintegrates instantaneously and does not require water to aid
swallowing. The Zydis matrix is composed of many materials designed to achieve a number of
objectives. To impart strength and resilience during handling, polymers such as gelatin, dextran
or alginates are incorporated. These form a glossy amorphous structure, which imparts strength.
To obtain crystallinity, elegance and hardness, saccharides such as Mannitol or sorbitol are
incorporated. Water is used in the manufacturing process to ensure production of porous units to
achieve rapid disintegration. Various gums are used to prevent sedimentation of dispersed drug
particles in the manufacturing process. Collapse protectants such as glycine prevent the
shrinkage of Zydis units during freeze drying process or long term storage. Zydis products are
packed in blister packs to protect the formulation from moisture in the environment.
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Figure no.17 Zydis Tecnology
Merits:
• Buccal pharyngeal and gastric regions are all areas of absorption from this formulation.
Any
• Pre-gastric absorption avoids first-pass metabolism and can be an advantage in drugs that
undergo a great deal of hepatic metabolism.
• The Zydis formulation self-preserving because the final water concentration in the freeze
dried
• Product is too low To\ allow for microbial growth.
• Patients who have difficulty swallowing oral medication due to dysphagia, stroke or
medical
• Conditions such as gastro esophageal reflux disease, multiple sclerosis or Parkinsons
disease.
• Pediatric patients.
• Patients who refuse or spit out oral medications, including patients with psychiatric or
behavioral disorders.
• Companion animals such as dogs and cats
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Demerits:
• The process of freeze-drying is a relatively expensive manufacturing process.
• The formulation is very lightweight and fragile, and therefore should not be stored in
• Backpacks or the bottom of purses.
• It has poor stability at higher temperatures and humiditys.
• The freeze-drying is time consuming process.
• It has poor physical resistance
• Loading of high dose of water-soluble drugs is not possible [72].
Orasolv technology:
This technology is patented by CIMA Labs. This includes use of effervescent
disintegrating agents compressed with low pressure to produce the MDTs. The OraSolv process
typically involves blending the microencapsulated API with magnesium oxide and mannitol to
aid in the release of the drug from the polymeric coating. These micro particles are further
blended with other excipients and loosely compressed to maintain some degree of tablet porosity
to aid dispersion. Compression forces need to be kept to a minimum so as not to disrupt the API
taste-masking coating. With OraSolv tablet technology, tablets are compressed to a hardness of
6-25 N and packaged in blister cards. The resultant tablet is relatively weak and friable and
requires specific patented packaging technology (PakSolv, CIMA Labs) was developed to
protect the tablets from breaking during transport and storage.
The OraSolv ODT technology uses taste-masked drug microparticles in a formulation
that enhances tablet disintegration. On contact with saliva, the effervescent system promotes
disintegration of the tablet. Carbon dioxide is generated by a reaction of the formulation
components upon exposure to water (saliva in the mouth). This causes a sensation in the mouth
that is pleasant to the patient and tends to stimulate further saliva reduction, which also aids in
disintegration.
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Advantages:
The OraSolv technology has been used for drug strengths in the range of 1 mg to 750 mg.
Depending on formulation and tablet size, the disintegration time of the tablet can be designed in
the range of 10 to 40 seconds
PakSolvR is a “dome-shaped” blister package that prevents the vertical movement of the
tablet within the depressions, because the diameter of the lower portion of the dome is too
narrow to accommodate the tablet. PakSolvR also offers light, moisture, and child resistance.
Disadvantages:
Both OraSolv and DuraSolv products are sensitive to moisture due to the presence of the
effervescent system and must be packaged appropriately [73].
Durasolv technology:
The DuraSolv technology has a formulation similar to the OraSolv technology,
combining taste masked drug micro particles with or without a low effervescence-containing
formulation, was developed by CIMA labs, consist of a drug, fillers and the lubricants. The
tablets are prepared by conventional tabletting equipment and have good rigidity. They can be
packed in the conventional tabletting equipment and have good rigidity.
Advantages:
DuraSolv technology is good for tablets having low amount (125 mcg to 500 mg) of
active ingredients and tablets are compressed to a greater hardness of 15-100 N, resulting in a
more durable ODT. As a result, this technology enables packaging flexibility; tablets can be
bottled and blistered.
Disadvantages:
The technology is not compatible with larger doses of active ingredients, because the
formulation is subjected to high pressure during compaction. The drug powder coating in
Durasolv may become fractured during compaction, exposing the bitter tasting drugs to the
patient taste buds [74].
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Wowtab technology:
Yamanauchi pharmaceutical company patented this technology. wow means without
water. The WOW in the WOWTAB signifies the tablet is to be given without water. The active
ingredients may constitute up to 50% w/w of the tablet. In this technique, saccharides of both
low and high mould ability are used to prepare the granules. Mould ability is the capacity of a
compound to be compressed. This technology utilizes sugar and sugar-like excipients. The two
different types of saccharides having high mold ability like maltose, mannitol, sorbitol, and
oligosaccharides (good binding property) and low mold ability like lactose, glucose, mannitol,
xylitol (rapid dissolution) are combined to obtain a tablet formulation with adequate hardness
and fast dissolution rate. Highly mould able substance has high compressibility and thus shows
slow dissolution. The combination of high and low mould ability is used to produce tablets of
adequate hardness [75].
Advantages:
• The Wowtab product dissolves quickly in 15 s or less.
• Wowtab product can be packed in both into conventional bottle and blister packs [75].
Flash dose technology:
This technology is patented by Fuisz. This system uses the combination of both
Shearform and Ceform technologies in order to mask the bitter taste of the drug. A sugar based
matrix, called Floss is used, which is made up of a combination of excipients (crystalline
sugars) alone or in combination with drugs. Nurofen meltlet, a new form of Ibuprofen, as a
mouth-dissolving tablet is the first commercial product prepared by this technology and launched
by Biovail Corporation.
Drawbacks
• The dosage form can accommodate only up to 600 mg of drug.
• Tablets produced are highly friable, soft and moisture sensitive. Therefore specialized
packing is required. [76].
.
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Oraquick technology:
K. V. S. Pharmaceuticals have a patent over this technology. It utilizes taste masking
microsphere technology called as micromask, which provides superior mouth feel over taste
masking alternatives, significant mechanical strength, and quick disintegration/dissolution of
product. Any kind of solvents are not utilized by taste masking process. Therefore it leads to
superior and fast efficient production. [77].
Pharmaburst technology:
SPI Pharma, New Castle has a patent over this technology. It utilizes the coprocessed
excipients to develop MDTs, which dissolves within 30-40 s. This technology involves dry
blending of drug, flavor, and lubricant followed by compression into tablets. Tablets obtained
have sufficient strength so they can be packed in blister packs and bottles [78].
Nanocrystal technology:
Elans, King of Prussia have a patent over this technology. This technology includes
Nanocrystal colloidal dispersions of drug substance are combined with water-soluble GRAS
(Generally Regarded as Safe) ingredients, filled into blisters, and lyophilized. The resultant
wafers are remarkably robust, yet dissolve in very small quantities of water in seconds. This
method avoids manufacturing process such as granulation, blending, and tabletting, which is
more advantageous for highly potent and hazardous drugs. As manufacturing losses are
negligible, this process is useful for small quantities of drug.
Advantages:
• Pharmacokinetic benefits of orally administered nanoparticles (< 2 microns) in the form
of rapidly disintegrating tablet matrix.
• Cost-effective manufacturing processes that utilize conventional, scalable unit operations.
• Exceptional durability, enabling use of conventional packaging equipment and formats
(i.e., bottles and/or blisters).
• Wide range of doses (up to 200 mg of API per unit)[79]. .
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Frosta technology:
A new technology called Frosta (Akina) was developed for making FMTs. The Frosta
technology utilises the conventional wet granulation process and tablet press for cost-effective
production of tablets. The Frosta tablets are mechanically strong with friability of < 1% and are
stable in accelerated stability conditions when packaged into a bottle container. They are robust
enough to be packaged in multi-tablet vials. Conventional rotary tablet presses can be used for
the production of the tablets and no other special instruments are required. Thus, the cost of
making FMTs is lower than that of other existing technologies. Depending on the size, Frosta
tablets can melt in < 10 s after placing them in the oral cavity for easy swallowing. The Frosta
technology is ideal for wide application of FMTs technology to various drug and nutritional
formulations. [80].
Dispersible tablet technology:
Leks in Yugoslavia have a patent over this technology. Dihydroergotoxine is poorly
soluble in water in the free base form. An improved dissolution rate of dihydroergotoxine
methane sulphonate was observed with dispersible tablets containing 0.8-10%, preferably about
4% by weight, of an organic acids. One of the essential excipients in the cimetidine formulation
was a disintegrating agent. The disintegrating agents include starch or modified starches,
microcrystalline cellulose, alginic acid, cross-linked sodium carboxymethyl cellulose, and
cyclodextrin polymers. Dihydroergotoxine and cimetidine, which were claimed to disintegrate in
less than 1 minute when in contact with water at room temperature [81].
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Table No: 5 Marketed ODT tablet:
Nimulid-MD Nimesulide Panacea Biotech
Zyrofmeltab Rofecoxib ZydusCadila
MOSID-MD Mosapride Citrate Torrent Pharmaceuticals
Feledine Melt Piroxicam Pfizer
Maxalt ODT Famotidine Merck
Remeron Sol Tab Mirtazapine Organon
Romilast Montelukast Ranbaxy
Manza BDT Olanzepine Orchid
Olanexinstab Olanzepine Ranbaxy
Valus Valdecoxib Glenmark
Rofaday MT Rofecoxib Lupin
Torrox MT Rofecoxib Torrent
Dolib MD Rofecoxi Panacea
Zilflam Rofecoxib Kapron
Orthoret MD Rofecoxib Biochem
Nexus MD Nimesulide Lexus
Nimex MD Nimesulide Mexon healthcare
Nisure MD Nimesulide Suzen Pharma
Olnium MD Nimesulide Olcare Lab
Sulbid Nimesulide Alpic Remedies
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LITRATURE REVIEW:
Velmurugan S et al., (2010) reported that Oral drug delivery remains the most preferred
route for administration of various therapeutic agents. Recent advances in technology
prompted researchers and scientists to develop oral disintegrating tablets (ODTs) with
improved patient convenience and compliance. ODTs are solid unit dosage form which
dissolve or disintegrate rapidly in the mouth without water or chewing. Novel ODT
technologies address many patient and pharmaceutical needs such as enhanced life cycle
management to convenient dosing particularly for pediatric, geriatric and psychiatric patients
who have difficulty in swallowing (Dysphagia) conventional tablet and capsules.
Technologies used for manufacturing of ODTs are either conventional technologies or
patented technologies. This review depicts the various aspects of ODT
formulation;superdisintegrants and technologies developed for ODT, along with various
drugs explored, evaluation tests and marketed formulations in this field.
Suhagiya V. K. et al., (2010) revealed that more than 50% of pharmaceutical products are
orally administered for several reasons and undesirable taste is one of the important
formulation problems that is Encountered with such oral products. Taste of a pharmaceutical
product is an important parameter governing compliance. Hence taste masking of oral
pharmaceuticals has become important tool to improve patient compliance and the quality of
treatment especially in pediatrics. Different methods have been suggested for masking of
taste of bitter drugs, which includes, coating of drug particles with inert agents, taste masking
by formation of inclusion complexes, molecular complexes of drug with other chemicals,
solid dispersion system, microencapsulation, multiple emulsions, using liposome's, Prodrugs
and mass extrusion method but ion exchange resin is one of most extensively used method to
overcome this problem. Ion-exchange resins (IER) have received considerable attention from
pharmaceutical scientists because of their versatile properties as drug-delivery vehicles. In the
past few years, IER have been extensively studied in the development of novel drug-delivery
systems (NDDSs) and other biomedical applications. Also recently the new applications of
ion exchange resin like ophthalmic drug delivery, anti-deliquescence, improve solubility, and
polymorphism has confirmed. This review highlights complete account of ion exchange resin
and its application in drug delivery research are-discussed.
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Shahi S.R. et al., (2008) revealed that etoricoxib is a novel, selective second generation
cyclo-oxygenase-2 inhibitor administered orally as an analgesic and anti-inflammatory drug
that is used for the treatment of osteoarthritis, rheumatoid arthritis and gouty arthritis. The
poor aqueous solubility of the drug leads to variable dissolution rates. In the present
investigation an attempt has been made to prepare oro-dispersible tablets of etoricoxib with
enhanced dissolution rate. The another purpose of the present investigation was to evaluate
effect of superdisintegrants like crospovidone (Polyplasdone XL), croscarmellose sodium
(ac-di-sol) and sodium starch glycolate (Primojel) on dissolution of poorly soluble, selective
COX-2 inhibitor in oro-dispersible tablets. In the study, the effect of superdisintegrants
specifically at 2 and 4 % level in oro-dispersible tablet formulation on the in vitro dissolution
was evaluated. These levels included optimum concentrations of selected superdisintegrants.
It was concluded that oro-dispersible tablets of etoricoxib with enhanced dissolution rate can
be made using selected superdisintegrants.
Rajnibala et al., (2012) reported that an oral solid dosage form should ideally disperse into
the primary particles from which it was prepared. Tablets and capsules which need rapid
disintegration, the inclusion of the right disintegrant is a prerequisite for optimal
bioavailability. Superdisintegrants are used to improve the efficacy of solid dosage forms.
This is achieved by decreasing the disintegration time which in turn enhances drug
dissolution rate. Disintegrants are substances or mixture of substances added the drug
formulation that facilitates the breakup or disintegration of tablet or capsule content into
smaller particles that dissolve more rapidly than in the absence of disintegrants.
Superdisintegrants are generally used at a low level in the solid dosage form, typically 1- 10
% by weight relative to the total weight of the dosage unit. The present study comprises the
various kinds of superdisintegrants which are being used in the formulation to provide focus
on the safer, effective drug delivery with patient's compliance.
Rewar S et al., (2014) reported that now-a-days, orodispersible drug delivery systems are
extensively used to improve bioavailability and patient compliance. Over the past three
decades, orodispersible tablets (ODTs) have gained considerable attention as a preferred
alternative to conventional tablets and capsules due to better patient compliance, improved
solubility and stability profiles. The purpose of the article is to review potential advancements
of ODT technology in drug delivery applications. Various techniques employed to prepare
ODTs include direct compression method, freeze drying and spray drying, tablet moulding,
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sublimation and mass extrusion. ODTs could be preferred choice especially with those drugs
sensitive to GI and for patients under category of pediatrics, geriatrics, bedridden, post-
operative and who may have difficulty in swallowing the conventional tablets and capsules.
ODTs are solid dosage forms containing medicinal substances which disintegrate rapidly,
usually in a matter of seconds, when placed on the tongue. ODTs render enhanced
acceptability due to its patient compliance as well as improved bioavailability and stability.
This article reviews recent trends undertaken to develop ODTs, new ODTs technologies
Margret chandira R et al., (2010) reported that the demand for mouth dissolving tablets has
been growing during the last decade especially for elderly and children who have swallowing
difficulties. Etoricoxib is a new non-steroidal anti-inflammatory drug (NSAID) with selective
cox-2 inhibitory activity, selective inhibition of cox-2 provides anti-inflammatory and
analgesic activity it is commonly used for osteo-arthritis, rheumatoid arthritis, primary
dysmenorrhea, post-operative dental pain and acute gout. The main criteria for mouth
dissolving tablets are to disintegrate or dissolve rapidly in oral cavity with saliva in 15sec to
60sec with need of water. The disintegrant used should fulfill the criteria by disintegrating the
tablets in specified time limit.in the present investigation variety of super disintegrant like
primogel, kollidone, Ac-Di-sol, L-HPMC, L-HPC, were selected and tablets were prepared
by direct compression method in different concentration like 4% and 8%. The prepared
tablets were evaluated for weight variation, hardness, friability, in vitro disintegration time,
wetting time, in vitro dissolution study, etc. formulation f-9 shows the lowest disintegration
time (44sec) and wetting time (52sec). In vitrodissolution studies revealed that formulation
F-9 containning 8% L-HPC showed 97% drug release at the end of 20min.
Jaysukh J et al., (2009) revealed that drug delivery systems are becoming increasingly
sophisticated as pharmaceutical scientists acquire a better understanding of the
physicochemical and biochemical parameters pertinent to their performance. Over the past
three decades, orally disintegrating tablets (ODTs) have gained considerable attention as a
preferred alternative to conventional tablets and capsules due to better patient compliance.
ODTs are solid dosage forms containing medicinal substances which disintegrate rapidly,
usually in a matter of seconds, when placed on the tongue. Products of ODT technologies
entered the market in the 1980s, have grown steadily in demand, and their product pipelines
are rapidly expanding. New ODT technologies address many pharmaceutical and patient
needs, ranging from enhanced life-cycle management to convenient dosing for paediatric,
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geriatric, and psychiatric patients with dysphagia. This has encouraged both academia and
industry to generate new orally disintegrating formulationsand technological approaches in
this field. The aim of this article is to review the development of ODTs, challenges in
formulation, new ODT technologies and evaluation methodologies, suitability of drug
candidates, and future prospects.
Alok Kumar Gupta et al., (2011) suggested that the convenience of administration and
improved patient compliance are important in the design of oral drug delivery system which
remains the preferred route of drug delivery inspite of various disadvantages. One such
problem can be solved in the novel drug delivery system by formulating “mouth dissolving
tablets” (MDTs) which disintegrates or dissolves rapidly without water within few seconds in
the mouth due to the action of superdisintegrant or maximizing pore structure in the
formulation. Mouth dissolving tablets are advantageous particularly for pediatric, geriatric
and mentally ill patients who have difficulty in swallowing conventional tablets and capsules.
The review describes the various formulation aspects, superdisintegrants employed and
technologies developed for MDTs, along with various excipients, evaluation tests, marketed
formulation and drugs used in this research area.
Sharma Chandan, et al., (2010) revealed that over a decade, the demand for development of
orally disintegrating tablets (ODTs) has enormously increased as it has significant impact on
the patient compliance. Orally disintegrating tablets offer an advantage for populations who
have difficulty in swallowing. Prescription ODT products initially were developed to
overcome the difficulty in swallowing conventional tablets with water among pediatric,
geriatric, and psychiatric patients with dysphagia. Today, ODTs are more widely available as
over-the-counter products for the treatment of allergies and cold and flu symptoms.
Technologies used for manufacturing of orally disintegrating tablets are either conventional
technologies or patented technologies. In conventional freeze drying, tablet molding,
sublimation, spray drying etc. and in patented Zydis technology, Orasolv technology,
Durasolv technology, Wow tab technology, Flashdose technology are important. Important
ingredients that are used in the formulation of ODTs should allow quick release of the drug,
resulting in faster dissolution. Evaluation of these tablets are done by following weight
variation, friability, tensile strength, wetting time, and water absorption ratio
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Muralidhar et al., (2010) found that Celecoxib is a selective cox-2 inhibitor is indicated to
the treatment of osteoarthritis, rheumatoid arthritis, acute painful primary dysmenorrhoea. It
is also superior to other NSAIDs, due to lower incidences of symptomatic gastrointestinal
ulcer complications than other NSAIDs. Celecoxib is practically insoluble in water. The
present investigation deals with enhancement of dissolution rate of celecoxib using mannitol
as carrier with different techniques like physical mixtures, kneading method and solvent
evaporation method. The dispersions were evaluated for drug content uniformity, dissolution
rate study, T50, DE20, ANOVA. The FTIR & DSC were used to characterize solid state of
solid dispersions. A marked increased in the dissolution rate was observed with all solid
dispersions, among that celecoxib : mannitol (1:4) KM. Showed maximum drug release
which was selected for formulation of tablets and evaluated for drug release characteristics.
The promising formulation (F2) was then compared with existing marketed product, the
release profiles was studied in water containing 2 % SLS. The release study showed that
these are fast release formulations of celecoxib. So it is clearly evident that F2 and marketed
product are greater than the pure drug .F2 subjected to stability studies the formulation was
found to be stable for 4 weeks at 400c, with insignificant change in the hardness,
disintegration time and in-vitro drug release pattern.
Seong Hoon Jeong et al., (2004) reported that fast disintegrating tablets (FDTs) have
received ever-increasing demand during the last decade, and the field has become a rapidly
growing area in the pharmaceutical industry. Upon introduction into the mouth, these tablets
dissolve or disintegrate in the mouth in the absence of additional water for easy
administration of active pharmaceutical ingredients. The popularity and usefulness of the
formulation resulted in development of several FDT technologies. The is review describes
various formulations and technologies developed to achieve fast dissolution/dispersion of
tablets in the oral cavity. In particular, this review describes in detail FDT technologies based
on lyophilization, molding, sublimation, and compaction, as well as approaches to enhancing
the FDT properties, such as spray drying, moisture treatment, sintering, and use of sugar-
based disintegrant. In addition, taste-masking technologies.
13. Yogyata S. Pathare et al., (2013) revealed that Current developments in the technology
have presented viable dosage alternatives from oral route for pediatrics, geriatric, bedridden,
nauseous or noncompliant patients. Oral thin film, a new drug delivery system for the oral
delivery of the drugs, was developed based on the technology of the transdermal patch. Fast-
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dissolving oral thin film is a solid dosage form, which disintegrate or dissolve within 1 min
when placed in the mouth without drinking of water or chewing. Oral film includes various
ingredients for its formulation which includes polymers, active pharmaceutical ingredient,
film stabilizing agents, sweeteners, flavors, colors, saliva stimulating agents, preservatives,
surfactants etc., but the first and far most a very essential ingredient which helps in film
formation is a polymer. Fast dissolving film is prepared using hydrophilic polymers that
rapidly dissolves on the tongue or buccal cavity, delivering the drug to the systemic
circulation via dissolution when contact with liquid is made. Water-soluble polymers are used
as film formers for fast dissolving films. The water-soluble polymers achieve rapid
disintegration, good mouth feel and mechanical properties to the films. Fast-dissolving oral
thin film offer fast, accurate dosing in a safe, efficacious format that is convenient and
portable, without the need for water or measuring devices. In this review article the different
polymers used for preparation of fast dissolving oral thin film like pullulan, gelatin, sodium
alginate, pectin, rosin, starch, chitosan are discussed together with their physicochemical
properties and film forming properties.
Priyanka Nagar et al., (2011) suggested that oral delivery is currently the gold standard in
the pharmaceutical industry where it is regarded as the safest, most convenient and most
economical method of drug delivery having the highest patient compliance. Formulation of a
convenient dosage form for oral administration, by considering swallowing difficulty
especially in case of geriatric and pediatric patient leads to poor patient compliance. To
troubleshoot such problems a new dosage form known as orally disintegrating tablet (ODT),
has been developed which rapidly disintegrate & dissolve in saliva and then easily swallowed
without need of water which is a major benefit over conventional dosage form. In addition,
patients suffering from dysphasia, motion sickness, repeated emesis and mental disorders
prefer such preparation because they cannot swallow large quantity of water. Further, drugs
exhibiting satisfactory absorption from the oral mucosa or intended for immediate
pharmacological action can be advantageously formulated in such type of dosage form. The
popularity and usefulness of the formulation resulted in development of several ODT
technologies for preparation. The current article is focused on ideal characteristics,
advantages and disadvantages, formulation aspects, formulation technologies, evaluation of
products and future potential.
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AshishGarg et al., (2013) reported that conventional dosage forms like tablets and capsules
are now days facing the problems like dysphagia, resulting in the high incidence of non
compliance and making the therapy ineffective. To obviate the problems associated with
conventional dosage forms, mouth dissolving tablets have been developed having good
hardness, dose uniformity, easy administration and serves as the first choice of dosage form
for paediatrics, geriatrics and travelling patients. The MDTs were developed with an aim of
having sufficient hardness, integrity and faster disintegration without water. Fast dissolving
tablets are disintegrating and/or dissolve rapidly in the saliva without the need for water.
Some tablets are designed to dissolve in saliva remarkably fast, within a few seconds, and are
true fast-dissolving tablets. Others contain agents to enhance the rate of tablet disintegration
in the oral cavity, and are more appropriately termed fast-disintegrating tablets, as they may
take up to a minute to completely disintegrate. This tablet format is designed to allow
administration of an oral solid dose form in the absence of water or fluid intake. Such tablets
readily dissolve or disintegrate in the saliva generally within <60 seconds.
Sanjay Singh et al., (2009) revealed that Methods to improve patients compliance have
always attracted scientists towards the development of fancy oral drug delivery systems.
Among them, mouth dissolving drug delivery systems (MDDDS) have acquired an important
position in the market by overcoming previously encountered administration problems and
contributing to extension of patent life. MDDDS have the unique property of rapidly
disintegrating and/or dissolving and releasing the drug as soon as they come in contact with
saliva, thus obviating the requirement of water during administration. Therefore, these dosage
forms have lured the market for a certain section of the patient population which includes
dysphagia, bed ridden, psychic, geriatric and pediatrics patients. Several techniques have
been developed in the recent past, to improve the disintegration quality of these delicate
dosage forms without affecting their integrity. This article focuses on the technologies
available and the advances made so far in the field of fabrication of mouth dissolving tablets.
J.R. Vane et al., (2002) suggested that cyclooxygenase (COX) is the pivotal enzyme in
prostaglandin biosynthesis. It exists in two isoforms, constitutive COX- 1 (responsible for
physiological functions) and inducible COX-2 (involved in inflammation). Inhibition of COX
explains both the therapeutic effects (inhibition of COX-2) and side effects (inhibition of
COX- 1) of non-steroidal anti-inflammatory drugs (NSAIDs). A NSAID which selectively
inhibits COX-2 is likely to retain maximal anti-inflammatory efficacy combined with less
toxicity. The activity of a number of NSAlDs has been investigated in several test systems,
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showing that most of those marketed have higher activities against COX-1 or are equipotent
against both isoforms. Adverse event data of marketed NSAIDs show a relationship between
a poor safety profile and more potent inhibition of COX-1 relative to COX-2. There are
several new non-steroidal COX-2 inhibitors in development. The most clinically advanced is
meloxicam, which consistently demonstrates higher activity against COX-2 than COX- 1 in
several test systems.
DaljitMasih1 et al., (2013) suggested that conventional dosage form such as tablets and
capsules are the most popular among all dosage forms existing today because of its
convenience of self-administration, compactness and easy manufacturing. However these
dosage forms are facing problems like hand tremors, dysphasia in case of geriatric patients,
the underdeveloped muscular and nervous systems in young individuals and in case of
uncooperative patients, the problem of swallowing is common phenomenon which leads to
poor patient compliance. To overcome these problems, mouth dissolving tablets have been
developed, which having good hardness, dose uniformity, easy administration and serves as
the first choice of dosage form for pediatrics, geriatrics and travelling patients. This report
summarizes the details of ingredients used in preparation of mouth dissolving tablets;
conventional manufacturing techniques for mouth dissolving tablets; patented technologies
for preparation of mouth dissolving tablets; evaluation of mouth dissolving tablet; and
mechanism of action of mouth dissolving tablets.
Jody K. Takemoto et al., (2008) reported that the NSAID etoricoxib is a selective inhibitor
of cyclo-oxygenase 2 (COX-2), approved for treatment of patients with chronic arthropathies
and musculoskeletal and dental pain. The rate of absorption of etoricoxib is moderate when
given orally (the maximum plasma drug concentration occurs after ~1 hour), and the extent of
absorption is similar with oral and intravenous doses. Etoricoxib is extensively protein bound,
primarily to plasma albumin, and has an apparent volume of distribution of 120 L in humans.
The area under the plasma concentration-time curve (AUC) of etoricoxib increases in
proportion to increasing oral doses between 5 and 120 mg. The elimination half-life of ~20
hours in healthy subjects enables once-daily dosing. Etoricoxib iseliminated following
biotransformation to carboxylic acid and glucuronide metabolites that are excreted in
urineandfaeces, with little of the drug (<1%) being eliminated unchanged in the urine.
Etoricoxib is metabolized primarily by the cytochrome P450 (CYP) 3A4 isoenzyme. Plasma
concentrations (AUC) of etoricoxib appear not to be different in patients with chronic renal
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insufficiency compared with individuals who have normal renal function. Compared with
healthy subjects, it has been reported that the AUC is increased by approximately 40% in
patients with moderate hepatic impairment. No inhibitory effects on CYP2C9, 2C19, 2D6,
2E1 or 3A4 are expected to occur with etoricoxib. Coadministration of etoricoxib with other
drugs has been examined only to a limited extent, thus further assessment is necessary.
Etoricoxib has been assessed for the management of several specific disease states, including
pain, osteoarthritis, and rheumatoid arthritis, and has shown similar efficacy in comparison
with traditional NSAIDs (including naproxen, diclofenac and ibuprofen) in these conditions.
Etoricoxib has demonstrated a significant reduction in gastrointestinal toxicity compared with
many traditional NSAIDs. The renal adverse effects of etoricoxib appear to be similar to
those of other NSAIDs, and the cardiovascular adverse effects of this selective COX-2
inhibitor require further clinical scrutiny. Further study is necessary to delineate the relevance
of the pharmacokinetic disposition in terms of the clinical benefits and risks of etoricoxib
compared with other options in the clinical arsenal.
Masoom Raza Siddiqui et al., (2012) reported that the development of the pharmaceuticals
brought a revolution in human health. These pharmaceuticals would serve their intended only
if they are free from the impurities and are administered in appropriate amount. To make
drugs serve their purpose various chemical and instrumentation method were developed at
regular intervals which are involved in the estimation of drugs. These pharmaceuticals may
develop impurities at various stages of their development, transportation and storage which
makes the pharmaceutical risky to be administered thus it must be detected and quantitated.
Md. HasanuzzamanShohag et al., (2011) reported that the aim of this study was to compare
the pharmacokinetic properties of two etoricoxib (CAS 202409-33-4) 60 mg formulations,
namely Etocox-60. (test product) and reference product, and to evaluate whether these two
formulations meet the FDA criteria to assume bioequivalence. Twenty-four healthy
volunteers were enrolled into this randomized, single-dose, 2-way crossover, open-label
pharmacokinetic study. Subjects were randomly assigned to receive the test formulation
followed by the reference formulation or vice versa as a single dose of 60 mg tablets after 12
h overnight fasting, with a washout period of two weeks. Following oral administration,
blood samples were collected at 0 (baseline), 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0,
24.0, 48.0, 72.0, 96.0, and 120.0 h. Serum concentration of etoricoxib was assessed using a
high performance liquid chromatographic- UV spectrometry procedure. The pharmacokinetic
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parameters were determined by the non-compartmental method. After administering a single
dose of 60 mg of each etoricoxib formulation, the obtained mean (SD) values for the test and
reference products were 1.26 (0.33) and 1.29 (0.35) lg/ml for Cmax; 3.25 (2.64) and 2.63
(1.40) h for tmax; 29.63 (8.31) and 30.40 (5.85) h · lg/ml for AUC0–120; and 31.84 (10.97)
and 33.00 (8.10) h · lg/ml for AUC0–1, respectively. The mean t1/2 was found 27.99 (7.87) h
and 29.84 (7.93)h for test and reference product respectively. From paired t-test, no
significant differences were observed (p > 0.05) for any pharmacokinetic parameters. After
analysis of variance, no period, sequence or formulation effects were observed for any
pharmacokinetic property. The 90% confidence intervals of the test/reference mean ratios of
the in-transformed AUC0–120, AUC0–1 and Cmax mean values were 95.90% (85.37%–
107.74%), 94.69% (84.43%–106.20 %) and 97.87% (85.54%–111.98 %), respectively, which
fell within the predetermined FDA bioequivalence range of 80%–125%. This single-dose
study found that the test and reference formulations of etoricoxib met the regulatory criteria
for bioequivalence in terms of both rate and extent of absorption.
Subhashis Chakraborty et al., (2009) reported that mouth dissolving tablets are well
established dosage forms available in the market. The numerous advantages that they offer to
the patients in terms of compliance as well as to the manufacturers in terms of huge revenues
by line extension of products are well known. This article attempts to present a detailed
review regarding technological advances made so far in the area of evaluation of mouth
dissolving tablets with respect to special characteristics of these unique dosage forms. In the
absence of any available standardized method, the authors recommendation on criticalissues
in the field may be considered.
Patra S, et al., (2010) reported that the present study was carried out in order to mask the
bitter taste of the etoricoxib by complexation with cation-exchange resin, Indion 204. The
drug resin complexes (DRC) were prepared by batch process and efficient drug loading was
obtained by using inactivated form of resin in the drug-resin ratio 1:3.3 with 30 min swelling
time of resin in 25 mL of water with 5 min stirring time. Drug-resin complexes were
characterized for dissolution studies and spectral studies. Drug release from drug-resin
complex in salivary pH was insufficient to impart bitter taste. Volunteers rated the drug resin
complex as tasteless and agreeable.
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Inderbir Singh et al., (2010) reported that the etoricoxib is an antiinflammatory and
analgesic agent in the treatment of arthritis, dysmenorrhoea, and acute dental surgery pain
and is having a bitter taste. The present study is designed to mask the bitter taste of etoricoxib
by complexation with weak cation exchange resins (Indion 214, 234 and 414) in order to
increase its compatibility and patient compliance. Drug resinates were characterized by FTIR
and XRD analysis methods. Drug resinates were evaluated by sensory taste evaluation test.
Indion 234 resin was showing good taste masking ability compared to Indion 214 and 414.
The in vitro drug release (after 60 minutes) was found to be 95%, 90% and 82% for F 234 III,
F 414 III and F 214 respectively
David Rodrigues et al., (2003) suggested that etoricoxib (100 μCi/dose) was administered
to six healthy male subjects (i.v., 25 mg; p.o., 100 mg). Following the i.v. dose, the plasma
clearance was 57 ml/min, and the harmonic mean half-life was 24.8 h. Etoricoxib accounted
for the majority of the radioactivity (∼75%) present in plasma following both i.v. and p.o.
doses. The oral dose, administered as a solution in polyethylene glycol-400, was well
absorbed (absolute bioavailability of ∼83%). Total recovery of radioactivity in the excreta
was 90% (i.v.) and 80% (p.o.), with 70% (i.v.) and 60% (p.o.) excreted in urine and 20% in
feces after either route of administration. Radiochromatographic analysis of the excreta
revealed that etoricoxib was metabolized extensively, and only a minor fraction of the dose
(<1%) was excreted unchanged. Radiochromatograms of urine and feces showed that the 6′-
carboxylic acid derivative of etoricoxib was the major metabolite observed (≥65% of the total
radioactivity). 6′-Hydroxymethyl-etoricoxib and etoricoxib-1′-N-oxide, as well as the O-β-D-
glucuronide conjugate and the 1′-N-oxide derivative of 6′-hydroxymethyl-etoricoxib, were
present in the excreta also (individually, ≤10% of the total radioactivity).
M. A. Radwan et al., (2012) revealed that the effect of chronic administration of etoricoxib
(EXB), in the absence or presence of St. Johns Wort (SJW), on its pharmacokinetic
parameters and blood pressure was investigated in rats. Methods: Rats were divided into 3
groups, each group received daily different oral treatment for 3 weeks. Rats blood pressures
were monitored initially, after 1 and 3 weeks of treatment, and after 1 week of discontinuing
dosing of both drugs. EXB pharmacokinetic parameters in the absence or presence of SJW
were calculated after 3 weeks. Key findings: SJW was significantly affected EXB
pharmacokinetic parameters. The steady state peak plasma concentration and terminal half-
life were reduced by 32 % and 91 %, respectively, due to a > 3 fold increase in its apparent
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clearance which is a concentration and time dependent effect. EXB was significantly
increased (P < 0.001) Rats blood pressure while, co-administration of EXB and SJW was not
significantly affect (P > 0.05) rats blood pressure as compared to the control. Conclusions:
Monitoring blood pressure of patients anticipated taking EXB for extended period should be
advised. The co-administration of SJW with EXB should be avoided since SJW would
greatly reduce EXB concentrations by inducing its metabolism.
Takemoto et al., (2008) reported that the NSAID etoricoxib is a selective inhibitor of cyclo-
oxygenase 2 (COX-2), approved for treatment of patients with chronic arthropathies and
musculoskeletal and dental pain. The rate of absorption of etoricoxib ismoderate when given
orally (the maximum plasma drug concentration occurs after ~1 hour), and the extent
of absorption is similar with oral and intravenous doses. Etoricoxib is extensively protein
bound, primarily toplasma albumin, and has an apparent volume of distribution of 120 L in
humans. The area under the plasma concentration-time curve (AUC) of etoricoxib increases
in proportion to increasing oral doses between 5 and120 mg. The elimination half-life of ~20
hours in healthy subjects enables once-daily dosing. Etoricoxib is eliminated following
biotransformation to carboxylic acid and glucuronide metabolites that are excreted in urine
and feces, with little of the drug (<1%) being eliminated unchanged in the urine. Etoricoxib is
metabolized primarily by the cytochrome P450 (CYP) 3A4 isoenzyme. Plasma
concentrations (AUC) of etoricoxib appear not to be different in patients with chronic renal
insufficiency compared with individuals who have normal renal function. Compared with
healthy subjects, it has been reported that the AUC is increased by approximately 40%in
patients with moderate hepatic impairment. No inhibitory effects on CYP2C9, 2C19, 2D6,
2E1 or 3A4 are expected to occur with etoricoxib. Co administration of etoricoxib with other
drugs has been examined only to a limited extent, thus further assessment is necessary.
Etoricoxib has been assessed for the management of several specific disease states, including
pain, osteoarthritis, and rheumatoid arthritis, and has shown similar efficacy in comparison
with traditional NSAIDs (including naproxen, diclofenac and ibuprofen) in these conditions.
Etoricoxib has demonstrated a significant reduction in gastrointestinal toxicity compared with
many traditional NSAIDs. The renal adverse effects of etoricoxib appear to be similar to
those of other NSAIDs, and the cardiovascular adverse effects of this selective COX-2
inhibitor require further clinical scrutiny. Further study is necessary to delineate the relevance
of the pharmacokinetic disposition in terms of the clinical benefits and risks of etoricoxib
compared with other options in the clinical arsenal.
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James Klancke, et al., (2003) reported that orally disintegrating tablets (ODT) are solid
dosage forms that disintegrate in the oral cavity leaving an easy-to-swallow residue. The
disintegration times are generally less than one minute. For orally disintegrating tablets, taste-
masking of bitter or objectional-tasting drug substances is critical. The taste-masking aspect
plays a significant role in dissolution method development, specifications, and testing. The
USP 2 paddle apparatus is the most suitable and common choice for orally disintegrating
tablets. Discriminating, robust dissolution methods are extremely useful for monitoring
process optimization and changes during scale-up of taste-masked bulk drug and tablet
manufacture.
Szakonyi G, et al ., (2013) revealed that one of the promising approaches to predict in vivo
disintegration time of orally disintegrating tablets (ODT) is the use of texture analyzer
instrument. Once the method is able to provide good in vitro in vivo correlation (IVIVC) in
the case of different tablets, it might be able to predict the oral disintegration time of similar
products. However, there are many tablet parameters that influence the in vivo and the in
vitro disintegration time of ODT products. Therefore, the measured in vitro and in vivo
disintegration times can occasionally differ, even if they coincide in most cases of the
investigated products and the in vivo disintegration times may also change if the aimed
patient group is suffering from a special illness. If the method is no longer able to provide
good IVIVC, then the modification of a single instrumental parameter may not be successful
and the in vitro method must be re-set in a complex manner in order to provide satisfactory
results. In the present experiment, an optimization process was developed based on texture
analysis measurements using five different tablets in order to predict their in vivo
disintegration times, and the optimized texture analysis method was evaluated using
independent tablets.
Johannes Kraemer, et al., (2012) suggested that for industrially manufactured
pharmaceutical dosage forms, product quality tests and performance tests are required to
ascertain the quality of the final product. Current compendial requirements specify a
disintegration and/or a dissolution test to check the quality of oral solid dosage forms. These
requirements led to a number of compendial monographs for individual products and, at
times, the results obtained may not be reflective of the dosage form performance. Although a
general product performance test is desirable for orally disintegrating tablets (ODTs), the
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complexity of the release controlling mechanisms and short time-frame of release make such
tests difficult to establish. For conventional oral solid dosage forms (COSDFs), disintegration
is often considered to be the prerequisite for subsequent dissolution. Hence, disintegration
testing is usually insufficient to judge product performance of COSDFs. Given the very fast
disintegration of ODTs, the relationship between disintegration and dissolution is worthy of
closer scrutiny. This article reviews the current status of dissolution testing of ODTs to
establish the product quality standards. Based on experimental results, it appears that it may
be feasible to rely on the dissolution test without a need for disintegration studies for selected
ODTs on the market.
Ugurlu T, et al., (2015) This article summarizes the advantages of orally disintegrating
tablets (ODTs) as well as critical issues during evaluation of ODTs such as bioequivalence
and challenges and limitations of ODTs and finally present and the future of ODTs. ODTs
have received ever increasing demand and the field has become a rapidly growing area in the
pharmaceutical industry. Upon introduction into the mouth, these tablets dissolve or
disintegrate in the mouth in the absence of additional water. When ODTs are put on tongue
they disintegrate instantaneously, releasing the drug which dissolve or disperses in the saliva.
Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva passes down
in to the stomach. In such cases, bioavailability of a drug is significantly greater than those
observed from conventional tablet dosage form. The advantages of mouth dissolving dosage
form are increasingly being recognized in both, industry and academia. Their growing
importance has been underlined recently when European Pharmacopoeia adopted the term
“Orodispersible Tablet” as tablet that is to be place in the mouth where it disperses rapidly
before swallowing. ODTs have some challenges but solutions to overcome these challenges
were shown in this paper.
Bhupendra G Prajapati, et al., (2010) revealed that quetiapine fumarate bioavailability is
9%. Used in the treatment of schizophrenia. It is preferable to administer in the form of fast
disintegrating tablets used for depressive episodes, acute manic episodes associated with
bipolar I disorder at a short time. In present research work an attempt has been made to
prepare taste masked fast dissolving tablets of quetiapine fumarate were prepared by using
direct compression method. IR spectral analysis study showed that there was no drug
interaction with formulation additives of the tablet. The blend was examined for the
precompressional parameters results were within prescribed limits and indicated good free
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flowing property. The prepared tablets formulations were evaluated for post-compressional
parameters. All the post-compressional parameter are evaluated were prescribed limits and
results were within IP acceptable limits. Taste evaluation was performed on six healthy
human volunteers. The pure drug was felt bitter immediately after it was kept on the tongue
and the sense was even carried upto 5 min. However the bitterness of the drug was reduced or
even masked after complexation with Eudragit EPO in different ratios ( 1:0.5, 1: 1, 1:2, 1:3 ).
In case of 1: 0.5 ratios it was felt slightly bitter after 1 min and it is apparent from the results
that the increasing concentrations of the polymer have completely masked the bitter taste of
the drug. The disintegration time of 72 to 241 sec, and in-vitro drug release showed 96.88 -
98.92% within 9 min. Formulation A3 showed 98.91% release after 30 min, B3 and C3
showed 102.83, 99.44 % drug release in release in 30 min and 19 min for both formulations
respectively. The initial drug release for formulation C3 at 08 min is 79.62 %. From the
above observations, it is concluded that crospovidone 15 % shows better drug release profile
compared with other super disintegrants. So crospovidone was selected as best formulation.
The stability study conducted as per the ICH guidelines and the formulations were found to
be stable. The results concluded that bitterness of the drug was masked and showing
enhanced dissolution, improved effectiveness and hence better patient compliance.
Nalini Krishna Reddy M., et al., (2012) suggested that the aim of the present research was
to develop and evaluate taste masked orodispersible tablets (ODT) of naproxen. Over the past
three decades, orally disintegrating tablets have gained considerable attention as a preferred
alternative to conventional tablets due to better patient compliance. The most preferable route
of drug administration (e.g. oral) is limited to drug candidate that show poor permeability
across the gastric mucosa and those, which are sparingly soluble. A large majority of the new
chemical entities and many new existing drug molecules are poorly soluble, thereby limiting
their potential uses and increasing the difficulty of formulating bioavailable drug products.
Formulations were prepared using different superdisintegrants such as crosscaramellose
sodium, sodium starch glycolate, crosspovidone by direct compression method. The
properties of the formulations such as porosity, hardness, friability, wetting time, water
absorption ratio and disintegration time were investigated. All the formulations showed good
flow properties, low weight variation with rapid disintegration time and in-vitro dissolution.
The drug content of all the formulations was within the acceptable limits. The wetting time
for F6 & F9 formulations was below one minute. Formulation F9 which contains 6% of
crosspovidone showed least in- vitro disintegration time i.e., below 30 seconds and more than
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90% drug release within 8 minutes. The in-vitro drug release of Naproxen ODT were best
explained by Higuchis equation as the plots showed the highest linearity follwed by first
order and zero order, the Korsmeyer-Peppas release exponent “n” indicated that all
formulations showed a mechanism of both diffusion and erosion mechanism so called
anomalous( non- fickian) diffusion. The optimized formulation showed good in-vivo
disintegration time and palatable taste. The excipients used in this study did not alter
physicochemical properties of the drug, as tested by the Fourier transform infrared
spectroscopy (FTIR) and differential scanning calorimeter (DSC).
Ashwini Deshpande et al., (2014) suggested that oral administration of any dosage form is
most preferred route because of its self-medication, exact dosing of drug and easy
administration but one important drawback of oral route is that the difficulty in swallowing in
pediatric and geriatric patients and also the patients who have mental disorders. To overcome
these problems developing oral disintegrating tablet which is disintegrate in mouth within 30
secs. The onset of action is also satisfactory. The drug ondansetron which is used as
antiemetic in many situation like chemotherapy or radiotherapy induced emesis and also used
in the early onset of alcoholism. In this formulation ondansetron is taste masked by
polyethylene glycol 6000 because it is bitter drug. Many techniques used to formulate Oral
Disintegrating tablets. This dosage form is formulated by sublimation technique in which
Camphor is used as a sublimating agent. The prepared formulations were evaluated for
precompressional and post-compressional parameters. The Drug-Excipient compatibility
study was checked by UV for 15 days, these results indicated that there was no interaction
between dug and excipients. The values of pre-compressional parameters like bulk density &
tapped density were within acceptable limits and defined good free flowing properties. The
hardness test of all the formulations describes acceptable mechanical strength (2.5 to 3.5
kg/cm2). Friability of all formulations was less than 1%. Drug content was found to be high
(98.19 %- 105 %) and uniform in all the formulations. The tablet thickness was found to be
3.09 – 4.14 mm. The weight variation results indicated that average percentage deviation was
less then ± 7.5 %, which provides good uniformity in all formulations. The disintegration
time in preliminary trials declined significantly with surge in the concentration of
superdisintegrant& subliming agent (up to 3.5% & 10% concurrently).The % Drug release
from all formulation after 30 mins were within limit (> 96.40 %).
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Patil C. et al., (2011) revealed that the demand for orally disintegrating tablets of lamotrigine
has been growing during the last decade especially for the geriatric and pediatric patients.
Lamotrigine is a recognized drug for epilepsy, so development of an ODT of lamotrigine and
to evaluate the effect of various superdisintegrants on its disintegration time and release
profile was the prime objective of this research work. Tablets were prepared by direct
compression technique using 3 different superdisintegrants. Sodium starch glycolate,
croscarmellose sodium and crosspovidone XL-10 were used as superdisintegrants in
combinations to achieve optimum release profile, disintegration time and hardness. Direct
compression process was selected for this formulation of ODT tablets, because porous nature
is more in direct compression blend than wet granulation blend, so it will give faster
disintegration. Microcrystalline cellulose was used as diluent and mannitol, mint flavor and
sodium saccharin were used to enhance the organoleptic properties of tablets. The tablets
were evaluated for weight variation, hardness, friability, in-vitro disintegration time and drug
release characteristics. Hardness and friability data indicated good mechanical strength
around 3 kg/cm 2 for all the batches. The results of in-vitro disintegration time indicated that
the tablets dispersed rapidly in mouth within 8s. Dissolution study revealed release rate of
drug from the tablets was comparable with marketed tablet formulation of lamotrigine. It was
concluded that superdisintegrants addition technique is a useful method for preparing orally
disintegrating tablets by direct compression method.
Rakesh K. Patel1, et al., (2013) suggested that the objective of the current study was to
develop and optimize an orally disintegrating tablet formulation of metoprolol tartrate which
is an effective drug in the treatment of hypertension. Metoprolol tartrate orally disintegrating
tablets were prepared by direct compression method using different ingredients such as
mannitol, microcrystalline cellulose, aspartame, crospovidone, sodium starch glycolate,
croscarmellose sodium, powder flavours strawberry, peppermint & orange, colloidal silicon
dioxide and magnesium stearate. Tablets were evaluated for the physical properties, out of
which disintegration time and wetting time were considered as responses in a 3 full factorial
experimental plan. Results were statistically examined using design expert software and
polynomial mathematical equations; found to be statistically significant) for disintegration
time and wetting time data. The obtained results were used to generate optimized overlay
plot. The physical data from the numerical optimization were verified and found to be very
close to those predicted from the regression analysis. Accelerated stability study was also
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performed on the optimum formulation. All results were in accordance with the requirements
of a orally disintegrating tablet.
Mohammad Ali Shahtalebi, et al., (2015) suggested that the difficulty in swallowing is
common among all age groups, especially elderly and pediatrics. Orally disintegrating tablets
may constitute an innovative dosage form that overcome the problem of swallowing and
provide a quick onset of action. This study was aimed to formulate and evaluate an orally
disintegrating tablet (ODT) containing ondansetron while using semisynthetic and natural
superdisintegrants. Methods: Orodispersible tablets were prepared by direct compression
using natural superdisintegrant (Karaya gum) and semi-synthetic superdisintegrant
(croscarmellose). The prepared tablets were evaluated for hardness, friability, thickness, drug
content uniformity, water absorption and wetting time. A 32 factorial design was used to
investigate the effect of independent variables (amount of croscarmellose and karaya gum) on
dependent variables (disintegration time, friability and Q5 [cumulative amount of drug
release after 5 minutes]). A counter plot was also presented to graphically represent the effect
of independent variable on the disintegration time, friability and Q5 . The check point batch
was also prepared to prove the validity of the evolved mathematical model. The systematic
formulation approach helped in understanding the effect of formulation processing variable.
Results: According to the results of optimized batches, the best concentrations of
superdisintegrant were as follows: 7.88 mg Karaya gum and 7.78 mg croscarmellose gave
rapid disintegration in 31 seconds which showed 99% drug release within 5 minutes.
Conclusion: Karaya gum, a natural superdisintegrant, gives a rapid disintegration and high
release when used with synthetic superdisintegrant in formulation of ODT.
Vinay Jain, et al., ( 2012) suggested that a fast dissolving tablet was prepared by using
various Ingredients like crosepovidone , mannitol Sodium lauryl sulphate (SLS) , Magnesium
stearate was taken in different concentration (5-10% 50%, 2-6%, 1%,).Chemical
incompatibility studies confirmed that there is no interaction between drug and excipients
used in the formulations. All the batches are prepared by direct compression method. Effect
of disintegrants concentration on the disintegration behavior was evaluated, and all the tablets
were evaluated for hardness, friability, weight variation, water absorption ratio, dissolution,
and assay. Among the all preparations F8 emerged as the best formulation and showed
maximum dissolution rate.
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Rakhee K Kotecha, et al., (2017) suggested that a dosage forms that can rapidly dissolve or
disintegrate in the oral cavity have attracted a great deal of attention and hence Fast
disintegrating oral drug delivery system was developed. The present study was aimed at
formulation and evaluation of Metoclopramide Hydrochloride Oro-Dispersible Tablets.
Metoclopramide hydrochloride a derivative of paraaminobenzoic acid is a commonly
prescribed drug used for the management of gastrointestinal disorders such as gastric stasis,
gastroesophageal reflux and for the prevention of cancer chemotherapy- induced emesis. Oro-
dispersible tablets of Metoclopramide Hydrochloride was prepared by masking the bitter taste
by Aminoalkyl methacrylate copolymer (Eudragit EPO ), indion 294 ion exchange resin and
cyclodextrin in different concentration. All the batches were prepared by direct compression
method. All the batches of ODTS were evaluated for appearance, thickness, weight variation,
hardness, friability, in-vitro disintegration time, in-vitro dispersion time, wetting time,
content uniformity, in-vitro dissolution study. The stability studies for optimized formulation
(F15) were performed for 3 Months and then tablets were evaluated. The results obtained
were satisfactory and complies with the pharmacopeial specifications.
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Etoricoxib
Etoricoxib are also called non-steroidal anti-inflammatory drugs (NSAIDs), or
sometimes just 'anti-inflammatories'. Etoricoxib eases pain and swelling (inflammation) in
conditions like osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and it may also be
used for short periods of time in gout.
Figure no. 18 Structure of Etoricoxib
Chemical Name:
5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3'] bipyridiny
Etoricoxib, [5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) pyridine], is a
novel orally active agent that selectively inhibits cyclooxygenase-2 (COX-2). Etoricoxib is used
in the treatment of Rheumatoid arthritis, osteoarthritis, acute gout, chronic musculoskeletal pain
(including chronic low back pain), postoperative dental pain and primary dysmenorrhoea. The
drug is available as oral tablets, and the recommended dosage is between 60 and 120 mg/day. It
is a poorly soluble, lipophilic drug with estimated logP of 3.14 and pKa of 4.6. Etoricoxib
behaves like a weak base. Its aqueous solubility is low and highly pH-dependent.
Pharmacokinetic studies, however, show that when administered orally, etoricoxib is completely
and rapidly absorbed, with an oral bioavailability of up to 100%.
BCS OF ETORICOXIB:
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Etoricoxib, a widely prescribed anti-inflammatory drug belongs to class IΙ under BCS
and exhibit low and variable oral bioavailability due to its poor aqueous solubility.
COX-2 Inhibitors:
Prostaglandins are made by two different enzymes cyclooxygenase-1 (cox-1) and
cyclooxygenase-2 (cox-2). The prostaglandins made by the two different enzymes have slightly
different effect on the body. Cox-2 inhibitors are NSAIDs that selectively block the cox-2
enzyme and not the cox-1 enzyme. Blocking this enzyme impedes the production of
prostaglandins by the cox-2 which is more often the cause the pain and swelling of inflammation
and other painful condition. Because they selectively blocking the cox-2 enzyme and not the
enzyme, these drug are uniquely different form traditional NSAIDs which usually both cox-1 and
cox-2 enzymes.
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Table No. 6 Drug profile:
Drug name Etoricoxib
Synonyms Etonian, Etonitazene, Etoolin, Etoricoxib,
Drug state Solid,
Drug type Small molecule
Category Rheumatoid arthritis, Ankylosing spondylitis treatment
Chemical name 5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3'] bipyridiny
Cas number 202409-33-4
CHEMICAL STRUCTURE
Etoricoxib
Chemical formula C18H15ClN2O2S
Drug brand Alcox Ecoxpic , Tory Torcxia,
Mechanism of action Like any other COX-2 selective inhibitor
Etoricoxib selectively inhibits isoform 2 of
cyclo-oxigenase enzyme (COX-2). This reduces
prostaglandins (PGs) generation from
arachidonic acid.
Route of administration Oral
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Table No. 7 Physicochemical Properties:
Appearance White to off-white powder
Molecular weight 358.842 g/moL
Solubility Etoricoxib is freely soluble in methanol, tetrahydrofuran, dimethyl
sulfoxide, methyl ethyl ketone, dimethyl formamide, and
chloroform.
Melting point 1340C
PKa  (strong acid) 19.69
PKa (strong base) 4.49
Storage Stored in a well closed container in a cool, dry place.
Absorption Approximately 75%
Protein binding 92%
Biological half life 22 hours
Water  solubility 0.00328 mg/ml
Site and mechanism of action COX-2 INHIBITORS
Available dosage forms 30, 60, 90, 120,
Adverse reactions Diarrhea swelling of the legs, ankles or feet.
High blood pressure. Dizziness headache.
Use Acute and chronic treatment of the signs and symptoms of
osteoarthritis and rheumatoid arthritis
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Figure no. 19 cox-2 mechanism actions
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Figure no. 20 cox-2 working
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Background:
Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory,
analgestic, and antipyretic properties. It is approved for the treatment of osteoarthritis,
rheumatoid arthritis, ankylosing spondylitis, and acute pain. Etoricoxib has also shown promise
in prevention of cancer, and has been used as an adjunct to surgery to reduce the number of
adenomatous colorectal polyps in patients with the hereditary colon cancer susceptibility
syndrome, familial adenomatous polyposis (FAP). The anti-inflammatory and painrelieving
properties of etoricoxib result from inhibition of prostaglandin (PG) synthesis by selective
inhibition of PG G/H synthase-2 (encoded by gene PTGS2).
The two PTGS isoforms, PTGS1 and PTGS2, are bisfunctional enzymes with both
cyclooxygenase (COX) and hydroperoxidase activities, but they are commonly referred to as
COX. Etoricoxib is a member of the subclass of NSAIDs, which were purposefully designed as
COX-2-selective inhibitors (pdCOX-2 inhibitors) and that are frequently called coxibs. Most
traditional NSAIDs (tNSAIDs) inhibit both COX isoforms however, some of them show a
degree of COX-2 selectivity that is similar to that of celecoxib, although they were developed
before COX-2 was discovered. PdCOX-2 inhibitors provide anti-inflammatory effects that are
comparable with tNSAIDs that inhibit both COX isoforms while reducing the risk of serious
gastrointestinal toxicity. Following its introduction to US market in December 1998, etoricoxib
quickly became one of the most frequently prescribed drugs for the relief of pain and
inflammation. However, the data supporting a favorable gastrointestinal toxicity profile were
much weaker than those of other compounds within the class. Etoricoxib, as well as other
selective and nonselective NSAIDs, have been under intense scrutiny since 2004, when two
pdCOX-2-selective inhibitors, rofecoxib and valdecoxib, were withdrawn from the market due to
an increased risk of cardiovascular events including myocardial infarction.
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Celocoxib and lumiracoxib were never approved in the US due to cardiovascular safety
concerns. Etoricoxib is the only pdCOX-2 inhibitor currently available in the US. For many
patients with both severe arthritis and intolerance to nonselective NSAIDs due to gastrointestinal
side effects, pdCOX-2 inhibitors provide significant clinical benefit. The clinical care of patients
requiring anti-inflammatory pain therapy, as well as those at high risk of colorectal adenomas,
would be greatly aided by measurements that identify the patients who will benefit from
etoricoxib, yet not suffer adverse events. This summary briefly reviews the pharmacokinetics of
etoricoxib and discusses the candidate genes mediating the diverse pharmacological profile of
etoricoxib. Knowledge of the pharmacogenomics of these pathways may help to achieve
personalization and optimization of etoricoxib therapy.
Pharmacokinetics:
After oral administration, etoricoxib is rapidly absorbed and achieves peak serum
concentration in approximately 3hrs. It is extensively metabolized in the liver, with very little
drug (<3%) being eliminated unchanged. The major routes of excretion for celecoxib are feces
and urine. Etoricoxib is metabolized primarily through methyl hydroxylation to form
hydroxyetoricoxib. This reaction is largely catalyzed by CYP2C9, although CYP3A4 also plays
a minor (<25%) role. Hydroxetoricoxib is further oxidized to form carboxyetoricoxib by
cytosolic alcohol dehydrogenases ADH1 and ADH2, and then conjugated with glucuronic acid
by UDP glucuronosyltransferases to form the 1-Oglucuronide. None of the metabolites are
pharmacologically active.
As etoricoxib metabolism is predominantly mediated by CYP2C9, polymorphisms in
CYP2C9 are likely to have a direct impact on etoricoxib pharmacokinetics and variability in drug
responses. Individuals who are poor metabolizers of CYP2C9 substrates (e.g. CYP2C93 allele
carriers) have an increased exposure to etoricoxib when compared with those with normal
CYP2C9 activity. Drugs that inhibit CYP2C9 should therefore be used with caution in patients
taking etoricoxib. Although not a substrate of CYP2D6, etoricoxib inhibits this metabolic
enzyme. Drugs that are metabolized by CYP2D6 (e.g. metoprolol ) should also be used with
caution in patients receiving etoricoxib due to potential risk of drug interaction.
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Example of celocoxip hepatocyte:
Figure no. 21 process of hepatocyte
Pharmacodynamics:
Etoricoxib exerts its anti-inflammatory and analgesic activities through blocking the
synthesis of various inflammatory prostanoids (PG). The prostanoids, which include PGs and
thromboxane, are the end products of fatty acid metabolism produced by tissue specific COX
enzymatic activity. These products are important physiological and pathological mediators that
are involved in a wide range of biological processes including inflammation, pain, cancer,
glaucoma, osteoporosis, cardiovascular diseases, and asthma. The production of the prostanoids
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(PG) is dependent on the availability of arachidonic acid (AA). Following stimulation of the cell
membrane by inflammatory or mitogenic signals, the first step in PG synthesis is the release of
AA from the cellular phospholipids through the action of either secretory (sPLA2, encoded by
gene PLA2G2A) or cytoplasmic (cPLA2, encoded by gene PLA2G4A) phospholipases. Once
AA is released, the two isoenzymes, COX-1 (encoded by PTGS1) and COX-2 (encoded by
PTGS2), catalyze the production of the prostanoids. As indicated above, this involves two
sequential reactions. The initial COX reaction converts AA into PGG2. The second reaction
reduces PGG2 to PGH2. PGH2 is then converted into active metabolites PGE2, prostacyclin
(PGI2), thromboxane (TxA2), PGD2, and PGF2a by the action of tissue-specific PG syntheses.
These active metabolites interact with specific prostanoid G-protein-coupled receptors to mediate
diverse physiological responses, such as inflammation, fever, blood pressure regulation, clotting,
and gastrointestinal protection.
The COX-1 and COX-2 enzymes exhibit distinct expression profiles and roles in
physiological processes. COX-1 is constitutively expressed in many cell types and is the major
COX isoform in gastric tissue. It is responsible for the protection of the gastric mucosa, which
led to the development of the COX-2 hypothesis that drugs targeted against COX-2 only would
have reduced upper gastrointestinal toxicity. Although COX-2 is highly inducible by
inflammatory stimuli such as cytokines, growth factors, and tumor promoters [28–31], it is also
constitutively expressed in some tissues, such as the vessel wall, the kidney, or the heart. Indeed,
the depression of the physiological formation of COX-2-dependent prostanoids in these tissues
has been identified as the molecular mechanism underlying the thrombotic cardiovascular
complications of COX-2 inhibition. Seven placebo-controlled, randomized trials with three
chemically distinct pdCOX-2 inhibitors, including etoricoxib, have documented the
cardiovascular risk. Of note, etoricoxib is now used at lower doses than in the trials that showed
its cardiovascular hazard. etoricoxib has 30-fold greater inhibitory activity against COX-2
compared with COX-1, and inhibits COX-1 only minimally at therapeutic concentrations.
Although the selectivity for COX-2 measured in vitro is lower for etoricoxib compared with
other drugs in the coxib class (e.g. rofecoxib, valdecoxib, lumiracoxib, and celocoxib), it is very
similar at therapeutic concentrations in vivo. Etoricoxib also retains more ability to inhibit COX-
1 compared with other coxibs; however, the consequences of this with regard to its therapeutic
efficacy and toxicity are not well understood
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Cardiovascular toxicity:
Data from clinical trials and case–control studies have been associated the use of
selective COX-2 inhibitors, rofecoxib, valdecoxib, and etoricoxib with an increased incidence of
myocardial infarction, stroke, and death due to cardiovascular causes. These toxicities were
uncovered as secondary endpoints during trials testing coxibs for colorectal adenoma prevention
and arthritis treatment. The US Food and Drug Administration currently mandate black-box
warnings of increased cardiovascular hazards for the entire NSAIDs class.
Available data suggest that this risk may increase with the duration of use and may also
vary by a patients individual baseline cardiovascular risk. For etoricoxib, the increased
cardiovascular risk seems to be exposure dependent; both the dose and the dosing interval may
be important factors in cardiovascular risk. In the Adenoma Prevention with etoricoxib (APC)
trial, etoricoxib  twice a day exhibited a greater than three-fold risk for combined endpoints of
cardiovascular death, myocardial infarction, stroke, or heart failure compared with placebo, and
200mg twice a day with a greater than two-fold risk.
Patients with higher baseline cardiovascular risk factors also tended to exhibit an
increased risk. An evaluation of 5-year outcome data from the APC trial found a significant
association between baseline cardiovascular risk factors and etoricoxib associated cardiovascular
events. The prevention of colorectal sporadic adenomatous polyps trial showed that the risk for
cardiac disorders was higher in those taking etoricoxib 400mg once daily than in those on
placebo. In contrast, a number of clinical studies and a meta-analysis failed to demonstrate clear
evidence of an increased thrombotic cardiovascular risk with etoricoxib doses of less than or
equal to 400mg daily compared with placebo.
These analyses included data comparing coxibs with other nonselective NSAIDs. It is
unclear whether nonselective NSAIDs also increase cardiovascular risk; therefore, these data
cannot assess the relative safety of coxibs. In a more conclusive study, a pooled analysis of six
randomized trials comparing etoricoxib with placebo concluded that cardiovascular risk for
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etoricoxib-treated patients increases with dose, and that a once-daily dose is associated with
lower cardiovascular risk than the twice daily dose.
Patients in the high baseline cardiovascular risk group exhibited a disproportionately
higher risk of an adverse event, whereas etoricoxib did not cause a significant increase in
cardiovascular events in the low-risk group, suggesting the importance of considering baseline
cardiovascular risk for appropriate patient selection. In response to these data, the American
Heart Association recommends that patients treated with etoricoxib use the lowest effective dose
for the shortest duration to minimize the potential risk for an adverse cardiovascular event.
Patients with existing cardiovascular disease or risk factors for cardiovascular disease may be at
greater risk and alternative therapy should be considered. The mechanism underlying the
increased cardiovascular risk of COX-2 inhibition has been studied extensively.
The clinical events associated with coxib cardiovascular toxicity are primarily thrombotic
in nature. The depression of COX-2-derived cardioprotective PGs, particularly PGI2, and
perhaps PGE2, by the coxibs removes a physiological restraint on mediators that induce
thrombosis, increase blood pressure, and promote a therogenesis. One of these mediators is
TxA2, which is synthesized by COX-1 action in platelets. Long term treatment with COX-2-
specific inhibitors may create a prothrombotic environment and predispose patients to belevated
cardiovascular risk. This may be particularly harmful for patients already predisposed to
thrombosis due to the presence of atherosclerotic plaques in coronary or cerebral arteries. It is
likely that the clinical safety of etoricoxib may depend on a fine balance of multiple factors,
especially given the complexity of the molecular system regulating a therothrombotic processes.
Interindividual variability in drug metabolism, differences in the half-life of the drug, the effect
on blood pressure, or endothelial function may all contribute to the toxicity profile of coxibs or
other NSAIDs
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Table no. 8 EXCIPIENT PROFILE OF POLACRILIN POTASSIUM
Synonyms Divenyl benzene,  potassium methacrylate polymer,
polacrilin potassium, indion 294
Chemical formula (C10H10.C4H6O2.K) X-
Description It is a very fine , white  to grayish-white odorless,
crystalline
Functional categories Ion exchange resin
Solubility Insoluble in water
Moisture content ≤10
Melting point 242.5 m2/g
storage It is stable and should be stored in a well closed
container in a cool, dry  place.
application Tablet disintegrant, taste masking, product meet specs
of polacrilin potassium.
Chemical structure
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Table no .9 EXCIPIENT PROFILE OF TARTARIC ACID
Synonyms Erythraric acid, tartaric acid, uvic acid, paratartaric
acid
Chemical formula C4H6O6
Description White crystalline powder
Functional categories Leavening agents, buffering  agents
Solubility Soluble in water
Melting point 171-1740C
Stability storage conditions Should be stored in a well closed container in a cool
place.
Incompatibilities Acetic acid, chromic acid glycol, nitric acid,
hydroxyl compounds, perchloric acid,
Application It used to food additives,
Chemical structure
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Table no.10 EXCIPIENT PROFILE OF PEARLITOL FLASH
synonyms D- mannital, mannite, unitolo M 200 , isotol,
pearlitol sd 200, osmosal,
Chemical formula C6H14O6
Description White crystalline powder
Functional categories OH
Melting point 167-1700C
Stability  and storage conditions Storied in a well closed container in a cool and
dry place,
application Anti- caking agents, free flowing agents,
stabilizer, diluents,
Chemical structure
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Table no.11 EXCIPIENT PROFILE OF CROSPOVIDONE
Synonyms Poly vinyl pyrolidone, crospovidone,
povidone,
Chemical formula C6H9NO
Descriptions White color fine powder , tasteless, odorless,
Functional categories Disintegrating  agents,
Solubility Insoluble in PVP, Soluble in water,
Melting point 1500C
Stability and storage conditions Stored in a well closed container in a cool
place,
Chemical structure
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Table no. 12 EXCIPIENT PROFILE OF CROSCARMELLOSE SODIUM
Synonyms Sodium carboxymethyl cellulose,
croscarmellose sodium,
Chemical formula C28H30Na8O27
Description White crystalline powder
Functional categories Disintegrating agents
Melting 150-1700C
Stability and storage Stored in a well closed container in a cool dry
place
Chemical structure
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Table no. 13 EXCIPIENT PROFILE OF SUCRALOSE
Synonyms Sucktastic , sucralfate, surase-isomaltase
Chemical formula C12H19Cl3O8
Description White crystalline powder
Functional categories Sweetening agents
Solubility Water
Melting point 1250C
Stability storage Stored in a well closed container
Molar mass 397.64g/mol
Chemical name 1,6-dichloro -1,6-dideoxy-β-D-fructofuranosyl-
4-chloro-4-deoxy- α-D-galactopyranoside,
Chemical structure
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Table no.14 EXCIPIENTS PROFILE OF TALC
Synonyms Talcum powder,  mineral , soaprock, talc,
French chalk, steatite
Chemical formula Mg3Si4O10(OH)2
Description Colorless
Functional categories Lubricant
Chemical name Hydrous magnesium silicate
Solubility Insoluble in water, slightly soluble in dilute
mineral acids
Melting point 15000C
Molecular weight 379.259g/mol
Chemical structure
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Table no.15 EXCIPIENTS PROFILE OF MAGNESIUM STEARATE
Synonyms Dolomol , magnesium stearate
Chemical formula Mg(C18H35O2)2
Description White color
Functional categories Lubricant
Molecular weight 591.27 g/mol
Solubility Soluble in water, slightly soluble in benzene
Melting point 88.50C
Chemical structure
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Table no.16 EXCIPIENTS PROFILE OF NEOTAME
Synonyms Neotame, neostriatal, neostriatum, neosystems,
Chemical  formula C20H30N2O5
Functional categories Sweetening agents
Description White crystalline powder
Melting point 81.00-84.000c
Chemical name (s)-3-((3,3diethylbutyl)amino)-4-(((s)-1-
methoxy-1-oxo-3-phenylpropan-2-yl)amino)-
4-oxobutanic acid
Chemical structure
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Table no.17 EXCIPIENTS PROFILE OF AEROSIL
Synonyms Aerosil ,aerosol, aerosinusitis
Chemical name Dioxosilane
Molecular formula Sio2
Description White color fine powder
Molecular weight 60.08 g/mol
Functional categories Bulking agents
Melting point 16100C (29300F)
Chemical structure
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DISEASE PROFILE
Etoricoxib is used for relieving pain and swelling of joints associated with Osteoarthritis.
Etoricoxib is used for relieving swelling, stiffness, and pain of joints caused due
to Rheumatoid arthritis. Etoricoxib is also used for the symptomatic treatment of ankylosing
spondylitis.
The main difference between osteoarthritis and rheumatoid arthritis is the cause behind
the joint symptoms. Osteoarthritis is caused by mechanical wear and tear on joints. Rheumatoid
arthritis is an autoimmune disease in which the bodys own immune system attacks the body's
joints.
Figure no. 22 Osteoarthritis bone
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Osteoarthritis:
Osteoarthritis (also known as OA) is a common joint disease that most often affects
middle-age to elderly people. It is commonly referred to as "wear and tear" of the joints, but we
now know that OA is a disease of the entire joint, involving the cartilage, joint lining, ligaments,
and bone. Although it is more common in older people, it is not really accurate to say that the
joints are just “wearing out.” It is characterized by breakdown of the cartilage (the tissue that
cushions the ends of the bones between joints), bony changes of the joints, deterioration of
tendons and ligaments, and various degrees of inflammation of the joint lining (called the
synovium).
This arthritis tends to occur in the hand joints, spine, hips, knees, and great toes. The
lifetime risk of developing OA of the knee is about 46%, and the lifetime risk of developing OA
of the hip is 25%, according to the Johnston County Osteoarthritis Project, a long-term study
from the University of North Carolina and sponsored by the Centers for Disease Control and
Prevention (often called the CDC) and the National Institutes of Health.
Osteoarthritis is a top cause of disability in older people. The goal of osteoarthritis
treatment is to reduce pain and improve function. There is no cure for the disease, but some
treatments attempt to slow disease progression.
Symptoms:
Osteoarthritis (OA) is caused by aging joints, injury, and obesity. OA symptoms include joint
pain and stiffness. Treatment depends on the affected joint, including the hand, wrist, neck, back,
knee, and hip, and involves medication and exercise. If you are overweight, weight loss may improve
OA symptoms.
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Figure no. 23 Osteoarthiritis erosion of bone
How do you treat osteoarthritis?
There is no proven treatment yet that can reverse joint damage from OA. The goal of
osteoarthritis treatment is to reduce pain and improve function of the affected joints. Most often,
this is possible with a mixture of physical measures and drug therapy and, sometimes, surgery.
Physical measures: Weight loss and exercise are useful in OA. Excess weight puts stress
on your knee joints and hips and low back. For every 10 pounds of weight you lose over 10
years, you can reduce the chance of developing knee OA by up to 50 percent. Exercise can
improve your muscle strength, decrease joint pain and stiffness, and lower the chance of
disability due to OA. Also helpful are support (“assistive”) devices, such as orthotics or a
walking cane, that help you do daily activities. Heat or cold therapy can help relieve OA
symptoms for a short time.
Certain alternative treatments such as spa (hot tub), massage, and chiropractic
manipulation can help relieve pain for a short time. They can be costly, though, and require
repeated treatments. Also, the long-term benefits of these alternative (sometimes called
complementary or integrative) medicine treatments are unproven but are under study.
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Drug therapy: Forms of drug therapy include topical, oral (by mouth) and injections (shots).
You apply topical drugs directly on the skin over the affected joints. These medicines include
capsaicin cream, lidocaine and diclofenac gel. Oral pain relievers such as acetaminophen are
common first treatments. So are nonsteroidal anti-inflammatory drugs (often called NSAIDs),
which decrease swelling and pain.
In 2010, the government (FDA) approved the use of duloxetine (Cymbalta) for chronic
(long-term) musculoskeletal pain including from OA. This oral drug is not new. It also is in use
for other health concerns, such as mood disorders, nerve pain and fibromyalgia.
Patients with more serious pain may need stronger medications, such as prescription
narcotics. Joint injections with corticosteroids (sometimes called cortisone shots) or with a form
of lubricant called hyaluronic acid can give months of pain relief from OA. This lubricant is
given in the knee, and these shots may help delay the need for a knee replacement by a few years
in some patients.
Surgery:
Surgical treatment becomes an option for severe cases. This includes when the joint has
serious damage, or when medical treatment fails to relieve pain and you have major loss of
function. Surgery may involve arthroscopy, repair of the joint done through small incisions
(cuts). If the joint damage cannot be repaired, you may need a joint replacement.
Supplements:
Many over-the-counter nutrition supplements have been used for osteoarthritis treatment.
Most lack good research data to support their effectiveness and safety. Among the most widely
used are calcium, vitamin D and omega-3 fatty acids. To ensure safety and avoid drug
interactions, consult your doctor or pharmacist before using any of these supplements. This is
especially true when you are combining these supplements with prescribed drugs
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Rheumatoid arthritis:
Rheumatoid arthritis (RA) is an autoimmune disease in which the bodys immune system
– which normally protects its health by attacking foreign substances like bacteria and viruses –
mistakenly attacks the joints. This creates inflammation that causes the tissue that lines the inside
of joints (the synovium) to thicken, resulting in swelling and pain in and around the joints. The
synovium makes a fluid that lubricates joints and helps them move smoothly.
If inflammation goes unchecked, it can damage cartilage, the elastic tissue that covers the
ends of bones in a joint, as well as the bones themselves. Over time, there is loss of cartilage, and
the joint spacing between bones can become smaller. Joints can become loose, unstable, painful
and lose their mobility. Joint deformity also can occur. Joint damage cannot be reversed, and
because it can occur early, doctors recommend early diagnosis and aggressive treatment to
control RA.
Rheumatoid arthritis most commonly affects the joints of the hands, feet, wrists, elbows,
knees and ankles. The joint effect is usually symmetrical. That means if one knee or hand if
affected, usually the other one is, too. Because RA also can affect body systems, such as the
cardiovascular or respiratory systems, it is called a systemic disease. Systemic means “entire
body.
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Figure no. 24 Rheumatoid arthritis bone
Figure no. 25 Rheumatoid arthritis of bone damage by immune system
Rheumatoid arthritis affected joint:
Here, the joint is inflamed due excess influx and accumulation of cells and fluid in the
synovium. The result is that the synovium appears red and swollen due to the production of extra
fluid. The swelling can cause the bone to erode into the joint space. Additionally, the affected
joint feels warm due to increased blood flow to this region. The joint starts paining due to the
following causes:
 The inflammation induces chemical production that affects the nerve endings.
 The synovial capsule gets stretched as a result of joint swelling.
The capsule continues to remain stretched despite bringing down the inflammation and
cannot effectively perform its function of anchoring the joint in place. This causes the joint to
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move abnormally without restraint. The joint becomes injured upon inflammation and gradually
gets destroyed upon repeated inflammation. In most cases, more than one joint is affected. Often,
the same joint is affected on both sides of the body.
Symptoms of Rheumatoid Arthritis:
Symptoms of Rheumatoid Arthritis appear on and off. If symptoms grow, it could mean
that the condition has become severe.
The typical symptoms of Rheumatoid Arthritis include:
 Joint pain accompanied by swelling.
 Stiffness
 Feeling fatigued and tired, depressed or irritable.
 Anemia
 Flu-like symptoms: Fever and sweating.
Certain rare symptoms include:
 Weight loss
 Eye inflammation
 Rheumatoid nodules (lumps of flesh found on the elbows or hands and feet).
 On rare occasions, inflammation in other parts of the body: lungs, blood vessels and
membranes lining the heart.
Lifestyle factors that could result in Rheumatoid Arthritis:
 Smoking
 Consuming high amounts of red meat
 Drinking a lot of coffee
Further, certain genetic factors can increase the risk of developing Rheumatoid Arthritis.
Additionally, symptoms seem to worsen in cold weather although the weather in itself does not
seem to impact disease development
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Diagnosis:
It would be advisable to seek help from a Rheumatologist- a doctor specialized in the
methods and techniques to diagnose and treat Rheumatoid Arthritis.
The Rheumatologist will probably perform blood tests and X-rays to help identify the extent
of damage and the course of future medication.
Ankylosing spondylitis:
Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing
spondylitis symptoms include pain and stiffness from the neck down to the lower back. The
spine's bones (vertebrae) fuse together, resulting in a rigid spine
Ankylosing spondylitis is a form of chronic inflammation of the spine and the sacroiliac
joints. The sacroiliac joints are located at the base of the low back where the sacrum (the bone
directly above the tailbone) meets the iliac bones (bones on either side of the upper buttocks) of
the pelvis. Chronic inflammation in these areas causes pain and stiffness in and around the spine,
including the neck, middle back, lower back, and buttocks. Over time, chronic inflammation of
the spine (spondylitis) can lead to a complete cementing together (fusion) of the vertebrae, a
process referred to as ankylosis. Ankylosis causes loss of mobility of the spine.
Figure no. 26 Ankylosing spondylitis
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The most common early symptoms of ankylosing spondylitis include:
 Pain and stiffness. Constant pain and stiffness in the low back, buttocks, and hips that
continue for more than three months. Spondylitis often starts around the sacroiliac joints,
where the sacrum (the lowest major part of the spine) joins the ilium bone of the pelvis in
the lower back region.
 Bony fusion. Ankylosing spondylitis can cause an overgrowth of the bones, which may
lead to abnormal joining of bones, called "bony fusion." Fusion affecting bones of the
neck, back, or hips may impair a person's ability to perform routine activities. Fusion of
the ribs to the spine or breastbone may limit a person's ability to expand his or her chest
when taking a deep breath.
 Pain in ligaments and tendons. Spondylitis also may affect some of the ligaments and
tendons that attach to bones. Tendonitis(inflammation of the tendon) may cause pain and
stiffness in the area behind or beneath the heel, such as the Achilles tendon at the back of
the ankle.
Figure no. 27 Ankylosing spondylitis bone damage
How Is Ankylosing Spondylitis Diagnosed?
The diagnosis of ankylosing spondylitis is based on several factors, including:
 Symptoms Findings of a physical exam X-rays of the back and pelvis
 Measurements of the chest when breathing
 Results of lab tests
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How is Ankylosing Spondylitis Treated:
There is no cure for ankylosing spondylitis, but there are treatments that can reduce discomfort
and improve function. The goals of treatment are to reduce pain and stiffness, maintain a good
posture, prevent deformity, and preserve the ability to perform normal activities. When properly
treated, people with ankylosing spondylitis may lead fairly normal lives. Under ideal circumstances, a
team approach to treat spondylitis is recommended. Members of the treatment team typically include
the patient, doctor, physical therapist, and occupational therapist. In patients with severe deformities,
osteotomy and fusion can be done.
 Physical and occupational therapy. Early intervention with physical and occupational
therapy is important to maintain function and minimize deformity.
 Exercise. A program of daily exercise helps reduce stiffness, strengthen the muscles around
the joints and prevent or minimize the risk of disability. Deep breathing exercises may help
keep the chest cage flexible. Swimming is an excellent form of exercise for people with
ankylosing spondylitis.
 Medications. Certain drugs help provide relief from pain and stiffness, and allow patients to
perform their exercises with minimal discomfort. Nonsteroidal anti-inflammatory drugs
(NSAIDs) -- such as ibuprofen, naproxen, and aspirin -- are the most commonly used drugs
for spondylitis treatment. In moderate to severe cases, other drugs may be added to the
treatment regimen. Disease-modifying antirheumatic drugs (DMARDs), such
as methotrexate (Rheumatrex), can be used when NSAIDs alone are not enough to reduce the
inflammation, stiffness, and pain. In addition, relatively new drugs called biologics
adalimumab (Humira), adalimumab-atto (Amjevita), a biosimilar to
Humira, certolizumab pegol (Cimzia), etanercept (Enbrel), etanercept-szzs (Erelzi), a
biosimilar to Enbrel, golimumab (Simponi Aria, Simponi), infliximab (Remicade), and
infliximab-dyyb (Inflectra), a biosimilar to Remicade, and secukinimab (Cosentyx)-- have
been FDA-approved for treating ankylosing spondylitis. Also,
the antidepressant Cymbalta has been approved for chronic back pain as
well. Steroid injections into the joint or tendon may be helpful in some cases.
 Surgery. Artificial joint replacement surgery may be a treatment option for some people with
advanced joint disease affecting the hips or knees.
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AIM AND OBJECTIVE
Aim of present study is investigated formulation development and evaluate of etoricoxib
orally disintegration tablet by using ion exchange resin technique, in different concentrations to
enhance the disintegration profile. Research is focused to improve the therapeutic efficacy of the
one of the most promising drug meant for the treatment of rheumatoid arthritis, osteoarthritis and
gout.
Objective:
• To formulate development and evaluate solid unit dosage form of etoricoxib orally
disintegrating tablet.
• To perform the drug – excipient compatibility studies as per ICH guidelines
• To study the disintegration time, taste masking of ion exchange resin complexation
technique
• To study the rate and mechanism of dissolution process.
• To study the stability of the formulated drug.
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PLAN OF WORK
The following experiment protocol was designed to prepare the predetermined aim of the present
study.
Preformulation study for AIP:
• AIP characterization (flow properties, particle size distribution)
• Solubility studies
• Drug-excipient compatibility studies (FTIR)
• UV method development
Formulation and evaluation of   ODT:
Preformulation study:
• Angle of repose
• Bulk density
• Tapped density
• Compressibility
• Hausner ratio
Postformulation study:
• Weight variation
• Hardness
• Thickness
• Friability
• Disintegration
• Dissolution
To carry out the Accelerated stability studies of the final formulated product as per ICH
guidelines.
Pa
ge
95
MATERIAL METHOD
Table no. 18 materials:
S no. Excipients Manufacture
1 Etoricoxib Acumen pharmaceutical
2 Polacrilin potassium FMC biopolymer Hyderabad
3 Tartaric acid Lubrizol mumbai
4 Pearlitol flash Avantor hyderabad
5 Crospovidone Lubrizol mumbai
6 Croscarmellose sodium IMc pharmaceutical
7 Sucralose Lubrizol mumbai
8 Neotame Avantor hyderabad
9 Orange flaver IMc pharmaceutical
10 Peperment flaver Avantor hyderabad
11 Sunset yellow Lubrizol Mumbai
12 Talc Avantor Hyderabad
13 Magnesium stearate IMc pharmaceutical
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LIST OF EQUIPMENTS
Table no .19 list of equipments:
S NO. INSTRUMENTATION MANUFACTURE/SUPPLIERS
1 Precision balance Afcoset, Mumbai
2 Vernier Labindia, Mumbai
3 Friabilator Pharmatest, Mumbai
4 Hardness tester Strong cob, Monsanto, Mumbai
5 Dissolution apparatus Labindia, Mumbai
6 Tablet compression machine (single
station)
Cadmach machinery co.., ahemdabad
7 Uv spectroscopy Shimadzu, japan,
8 Hot air oven Biotech india
9 FTIR spectroscopy Shimadzu, japan,
Preformulation studies:
Pre-formulation testing is an investigation of physical and chemical properties of a drug
substance alone and when combined with excipients. It is the first step in the rationale
development of dosage forms. Pre-formulation studies yield necessary knowledge to develop
suitable formulation. It gives information needed to define the nature of drug substance and
provide a dosage form. Hence, the following pre-formulation studies were performed for the
obtained sample of drug.
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• Organoleptic evaluation
• Drug – excipients compatibility
• FTIR drug – excipients compatibility
• Particle size distribution
• Angle of repose
• Bulk density
• Tapped density
• Compressibility index
• Hausners ratio
• Solubility studies
• Loss on drying
• UV method development for estimation of drug resin complex formation
• UV method development for estimation of drug
Post formulation study:
• Weight variation test
• Hardness
• Thickness
• Friability
• Disintegration time
• Assay
• Dissolution study
Organoleptic evaluation:
The organoleptic property of
• Color
• Taste
• Odor
• Flavor
Pa
ge
98
Drug – excipients compatibility:
Fourier transform infrared spectroscopy:
FT-IR stands for Fourier transform infrared, the preferred method of infrared
spectroscopy. In infrared spectroscopy, IR radiation is passed through a sample. Some of the
infrared radiations is absorbed by the sample and some of it is passed through (transmitted). The
resulting spectrum represents the molecular absorption and transmission, creating a molecular
fingerprint of the sample. Like a fingerprint no two unique molecular structures produce the
same infrared spectrum. This makes infrared spectroscopy useful for several types of analysis.
FT-IR samples were mixed with KBr in ratio 1:3 and pressed into pellets. Pellets were analyzed
at wavelength range 4000-450cm-1 with resolution of as 4cm-1 and number of scans
Drug – excipients physical compatibility:
The study of physical appearance,
• Color
• Shape
• Size
Particle size determination:
Table no. 20
S no. Sieve number Opening size (mm)
1 4 4.750
2 6 3.350
3 8 2.360
4 12 1.680
5 16 1.180
6 20 0.850
7 30 0.600
8 40 0.425
9 50 0.300
10 60 0.250
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Dry sieving method
An accurately weighed quantity of test specimen was placed on the top (coarsest) sieve,
and lid was replaced. The nest of sieves was agitated for 5 minutes. Then each sieve was
carefully removed from the nest without loss of material. Each sieve was reweighed, and the
weight of material on each sieve was determined. The weight of material in the collecting pan
was also determined in similar manner. The nest of sieves were reassembled and agitated for
5mins. Each sieve was removed and weighed, as previously described. Upon completion of the
analysis, the weights of material were reconciled. Total losses must not exceed 5% of the weight
of original test specimen.
Table no. 21 Classification of powder by fineness:
S no. Classification of powder Sieve opening (μm)
1 Very coarse >1000
2 Coarse 355-1000
3 Moderately fine 180-355
4 Fine 125-180
5 Very fine 90-125
Angle of repose:
The angle of repose is the maximum angle of a stable slope determined by friction,
cohesion and the shapes of the particles. When bulk granular materials are poured onto a
horizontal surface, a conical pile will form. The internal angle between the surface of the pile and
the horizontal surface is known as the angle of repose and is related to the density surface area,
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and coefficient of friction of the material. Material with a low angle of repose forms flatter piles
than material with a high angle of repose. In other words, the angle of repose is the angle a pole
forms with the ground.
Figure.28 angle of repose
Angle of repose was determined using funnel method. The height of the funnel was
adjusted in such a way that the tip of the funnel just touches the heap of the blends. Accurately
weighed blend is allowed to pass through the funnel freely on to the surface.  The height and
diameter of the powder cone was measured and angle of repose was calculated using the
following equation.
= −1( ℎ|)
h = height of pile,
r = radius of pile, and
Ө = angle of repose
Table no. 22 flow property of angle of repose:
S no. Flo property Angle of repose
1 Excellent 25-30
2 Good 31-35
3 Fair 36-40
4 Passable 41-45
5 Poor 46-55
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Bulk density:
Bulk density is ratio of given mass of powder and its bulk volume. Bulk density was
determined by measuring the volume of known mass of powder sample that has been passed
through the screen in to graduated cylinder or through volume measuring apparatus in to cup.
= / 0
Where M= mass of the powder;
V0=bulk volume of the powder.
Limits: It has been stated that the bulk density values having less than 1.2 g/cm3 indicates good
packing and values greater than 1.5 g/cm3 indicates poor packing.
Tapped density:
A known quantity of powder was transferred to a graduated cylinder and volume V0 was
noted. The cylinder fixed to a density determination apparatus, tapped for 500 times then reading
was observed. The density is achieved by mechanically tapped by a measuring cylinder
containing the powder sample. After observing the initial volume the cylinder is mechanically
tapped and volume reading were taken until little further volume changes is observed.
= /
Where
M = mass of the powder,
Vr = final tapping volume of the powder.
Compressibility index and Hausner ratio:
The compressibility index and Hausner ratio may be calculated using measured values of
bulk density and tapped density as follows:
=100 /
= /
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Table no.23
Flow properties and corresponding Angle of repose, Compressibility index and Hausner
ratio Acceptance criteria of flow properties:
S no. Flow property Angle of
repose(θ)
Compressibility
Index (%)
Hausner
ratio
1 Excellent 25-30 <10 1.00-1.11
2 Good 31-35 11-15 1.12-1.18
3 Fair 36-40 16-20 1.19-1.25
4 Possible 41-45 21-25 1.26-1.34
5 Poor 46-55 26-31 1.35-1.45
6 Very poor 56-65 32-37 1.46-1.59
7 Practically poor >66 >38 >1.6
Loss on drying:
The Loss on drying test is designed to measure the amount of water and volatile matters
in a sample when the sample is dried under specified conditions. The loss on drying of the blend
(1.5g) was determined by using electronic LOD (helium lamp) apparatus at 105°C.
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Weight variation test:
Twenty tablets were selected randomly and the average weight was determined using an
electronic balance (P/PI-203MDS model, Denver instruments). Tablets were weighed
individually and compared with the average weight.
Hardness test:
Hardness or tablet crushing strength (fc), the force required to break a tablet in a
diametric compression was measured using Monsanto tablet hardness tester. It is expressed in
Kg/cm2.
Thickness test:
Ten tablets were selected randomly and thickness was assessed using a Vernier
caliper/screw gauge.
Friability test:
Friability is the loss of weight of tablet in the container due to removal of fine particles
from the surface. Friability test is carried out to access the ability of the tablet to withstand
abrasion in packaging, handling and transport.
Friability of the tablets was determined using Roche friabilitor at 25 rpm/min for 4 min.
The device subjects the tablet to the combined effect of abrasion and shock in a plastic chamber
revolving at 25 rpm and dropping a tablet at I height of 6 inches in each revolution. Preweighted
sample of tablets was placed in the friabilator and were subjected to the 100 revolutions. Tablets
were dusted using a soft muslin cloth and reweighed. Twenty tablets were weighed and loss in
weight (%) was calculated. The friability (F) is given by the formula,
% Friability = [(W1-W2)100]/W1
Where, W1= Weight of tablet before test, W2 = Weight of tablet after test
Assay:
Standard stock solution:
30mg of drug resin was taken and added to respective media in a 200 ml volumetric flask
and volume was made up to 200 ml, resulting in a standard stock solution of 150mcg/ml.
Working stock solution:
From the above standard stock solution 1ml was taken and added to the respective buffer
media in 25ml volumetric flask and the volume was made up to 25ml. Two working stocks were
prepared and that they can be used for preparation of samples.
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Determination of absorption maxima:
6μg/ml solutions were taken to determine absorption maxima. Initially blank buffer
solution is kept and scanned in the region of 200-400 nm. Then sample was for analysis and
scanned at the same region. The absorption maximum was found to be, Hence all further analysis
was carried out at 263nm in pH7.0 phosphate buffer.
UV method development for estimation of drug:
Preparation of buffer media:
7.0pH Phosphate buffer:
0.38g of monobasic sodium phosphate and 10g of sodium laryl sulphate is taken in
1000ml of water and adjusted to PH 7.0 with sodium hydroxide.
Standard stock solution:
30mg of etoricoxib was taken and added to respective media in a 200 ml volumetric flask
and volume was made up to 200 ml, resulting in a standard stock solution of 100mcg/ml.
Working stock solution:
From the above standard stock solution 1ml was taken and added to the respective buffer
media in 25ml volumetric flask and the volume was made up to 25ml. Two working stocks were
prepared and that they can be used for preparation of samples.
Determination of absorption maxima:
6μg/ml solutions were taken to determine absorption maxima. Initially blank buffer
solution is kept and scanned in the region of 200-400 nm. Then sample was for analysis and
scanned at the same region. The absorption maximum was found to be, Hence all further analysis
was carried out at 263nm in pH7.0 phosphate buffer.
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Disintegration study:
The disintegration test determines whether dosage forms such as tablets, capsules,
suppositories disintegrate with in a prescribed time when placed in a liquid medium under the
prescribed experimental conditions. Disintegration is defined as the state in which no residue of
the unit under test remains on the screen of the apparatus or if a residue remains it consists of
fragments of disintegrated parts of tablet component part such as insoluble coating of tablets.
Disintegrants are agents added to tablet and some encapsulated formulations to promote the
breakup of the tablet and capsule “slugs into smaller fragments in an aqueous environment
there by increasing the available surface area and promoting a more rapid release of the drug
substance. They promote moisture penetration and dispersion of the tablet matrix. Tablet
disintegration has received considerable attention as an essential step in obtaining fast drug
release. Disintegrants are an essential component to tablet formulations. The ability to interact
strongly with water is essential to disintegrant function. Combinations of swelling and/or
wicking and/or deformation are the mechanisms of disintegrant action.
There are three methods of incorporating disintegrating agents into the tablet:
A. Internal Addition (Intragranular)
B. External Addition (Extragranular)
C. Partly Internal and External.
Dissolution test:
The dissolution rate of etoricoxib tablets prepared was studied in phosphate buffer of pH
7.0 using Disso 2000 (Labindia) 8-station dissolution test apparatus with a paddle stirrer at 50
rpm. A temperature 37±0.5 °C was maintained throughout the study. One tablet containing 60
mg of etoricoxib was used in each test. Samples of dissolution media (5ml) were withdrawn
through a filter (0.45µ) at different intervals of time, suitably diluted and assayed at 289 nm for
etoricoxib. The samples of dissolution fluid withdrawn at each time were replaced with fresh
fluid. The dissolution experiments were replicated three times each (n=3).
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FORMULATION DEVELOPMENT
Table no. 24:
S NO. INGREDIENT CATEGORY
1 Etoricoxib Pharmaceutical active ingredient
Table no.25:
S.NO. INGREDIENT CATEGORY
1 Indion 294 Ion Exchange Resin
2 Kyron T314 Ion Exchange Resin
Table no. 26 Excipients list:
S No. Excipients Category
1 Tartaric Acid Buffering Agent
2 Pearlital Flash Diluvant
3 Croscarmellose Sodium Disintegrating Agent
3 Crospovidone Disintegrating Agent
5 Sucralose Sweetening Agent
6 Neotame Sweetening Agent
7 Sunset Yellow Coloring Agent
8 Orange Flavor Flavoring Agent
9 Peppermint Flavor Flavoring Agent
10 Aerosil Glident
11 Talc Lubricant
12 Magnesium stearate Lubricant
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Table no. 27 Formation of drug resin complex
S
NO.
Ingredients Resin  complex  code (mg/T)
1
Etoricoxib
DRC1 DRC2 DRC3 DRC4 DRC5 DRC6
60.00 60.00 60.00 60.00 60.00 60.00
2 Indion 294 60.00 60.00 60.00 120.00 180.00 -
3 Tartaric acid - 25.00 50.00 50.00 50.00 50.00
4 Kyron t 314 - - - - - 180.00
5 Purified water q.s q.s q.s q.s q.s q.s
Preparation of complex:
The preparation is done by ion exchange resin complex technique. The drug and the resin
(indion294) are taken in the ratio of 1:3.
Resin activation process:
The resin activation process is nothing but the soaking of resin in water. The resin soaked
for 45 minutes in water and the resin swells.
PH adjustment:
The PH of activated resin is adjusted to 3-4 by using tartaric acid. The tartaric acid used as
the buffering agent.
Stirring process:
The PH adjusted resin and drug are mixed in a same beaker with mechanical stirrer for 8
hours in 1000 rpm. After completion of stirring (8 hours). Then the drug resin complex is set
aside stably for 12 hours. Two layers get separated. The upper layer (supernatant fluid) is water
and the lower layer (suspansoide) is drug resin complex.
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Drying of complex:
To collect the suspansoide it is dried to 50-600C for 4-5 hours in a hot air oven.
Finishing process:
After drying the drug resin complex it is checked for LOD. Then the drug resin complex
was collected.
Table no.28 Dispersion improvement/ taste formulation
S
NO.
Ingredient Dispersion improvement code
(mg/t)
Taste improvement code
( mg/t)
1 DRC-5
EDI-1 EDI-2 EDI-3 ETI-1 ETI-2 ETI-3
290.00 290.00 290.00 290.00 290.00 290.00
2 Croscarmellose
sodium
20.00 - 20.00 20.00 20.00 20.00
3 Crospovidone - 20.00 20.00 20.00 20.00 20.00
4 Pearlital flash 78.20 78.20 58.20 52.20 52.20 46.20
5 Sucralose - - - 6.00 - 6.00
6 Neotame - - - - 6.00 6.00
7 Sunset yellow 1 1 1 1 1 1
8 Orange flavor 0.50 0.50 0.50 0.50 0.50 0.50
9 Peppermint flavor 0.30 0.30 0.30 0.30 0.30 0.30
10 Aerosil 4.00 4.00 4.00 4.00 4.00 4.00
11 Talc 2.00 2.00 2.00 2.00 2.00 2.00
12 Magnesium
Stearate
4.00 4.00 4.00 4.00 4.00 4.00
Total 400.00 400.00 400.00 400.00 400.00 400.00
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Preparation of orally disintegration tablet:
To collect the drug + resin complex and excipients.
Sieving process:
The drug resin complex and excipients are passed through the sieve numbers 20, and 40
respectively.
The granules are collected.  The drug resin complex is one more time checked for LOD
content level.
Blending process:
The granules of drug resin complex and excipients are collected. And the granules are
blended.
Tablet compression process:
The blended granules were involved in direct compression process. The granules are
converted to the oral disintegration tablet.
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RESULT AND DISCUSSION
Organoleptic properties of etoricoxib:
Table no. 30 Properties of Etoricoxib:
S NO. Properties Observation
1 Description Etoricoxib is a yellow crystalline powder
2 Color Yellow ion oxide
Drug-excipient compatibility:
Drug-excipient compatibility is tabulated as follows:  Physical observation of drug-
excipient compatibility study
Table no. 31 Drug-Excipients compatibility:
S NO. Physical mixture Observation  3 month
250C/60%RH 400C/60%RH
1 Drug Yellow color Yellow color
2 Polacrilin potassium White crystal White crystal
3 Pearlitol flash White crystal White crystal
4 Crospovidone White powder White powder
5 Croscarmellose sodium White powder White powder
6 Sucralose White crystal White crystal
7 Neotame White crystal White crystal
8 Orange flavor Brownish Brownish
9 Peppermint flavor Brownish Brownish
10 Talc White powder White powder
11 Magnesium stearate White powder White powder
Fourier Transform-Infrared spectroscopy:
Drug excipient compatibility was analyzed using FT-IR. FT-IR was done using Perkin-
Elmer spectrum. All the samples were mixed properly with KBr in 1:3 ratios and were made into
pellets. Those pellets were analyzed. Each KBr disc was scanned over a wave number region of
4000-400 cm-1 using FT-IR Spectrophotometer.
Pa
ge
11
1
FTIR Spectrum of etoricoxib pure drug:
Figure 29 Etoricoxib pure drug
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FTIR Spectrum of etoricoxib placebo: (WITH OUT API)
Figure 30 Etoricoxib placebo (without drug)
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FTIR Spectrum of etoricoxib blend:
Figure 31 Etoricoxib blend
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FT-IR on the selected formulation prepared with different polymer and excipients
combination. The spectrum peak point of the formulation were similar with that of pure
etoricoxib, it clearly indicates that there are no polymer interaction.
Particle size determination:
The particle size was determined by using sieving method.
Table no.32
S NO. Ingredient Sieve number Particle size
1 Etoricoxib 20 0.850
2 Excipients 40 0.425
FLOW PROPERTIES OF ETORICOXIB:
Table no.33
S.NO Angle of Repose
Mean ± SEM
Bulk density
Mean ± SEM
Tapped density
Mean ± SEM
Carr”s Index
Mean ± SEM
Hausners Ratio
(H) Mean ± SEM
1 22.62 0.64 0.63 14.51 1.22
2 22.91 0.60 0.65 14.41 1.24
3 23.95 0.63 0.67 14.74 1.26
23.16 ± 0.403 0.62 ± 0.01 0.66 ± 0.011 14.55 ± 0.097 1.24±0.01
All values are expressed as mean ± SEM for three determinations
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Evaluation flow properties of blend:
Table no. 34 Evaluation parameter:
Formulation
code
Evaluation parameter
Angle of
repose
Bulk
density
(g/cm3)
Tapped
density
(g/cm3)
Compressibility
Index (%)
Hausners
ratio
Flowability
EDI 1 25.15 0.571 0.699 14.64 1.17 Excellent
EDI 2 26.35 0.586 0.684 14.32 1.16 Excellent
EDI 3 24.21 0.579 0.674 14.09 1.20 Fair
ETI 1 28.65 0.568 0.667 14.84 1.17 Excellent
ETI 2 23.95 0.578 0.678 14.74 1.18 Excellent
ETI 3 27.84 0.588 0.688 17.53 1.23 Fair
Inference:
Compressibility index, angle of repose, bulk density, tapped density and hausner ratio of
trial batches were computed and found that all blends possess good flow properties and hence
suitable for direct compression of blends into tablets.
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Saturation solubility:
. Table no. 35
S NO. Medium Solubility
1 Methanol Soluble
2 Water Insoluble
3 7.0 phosphate buffer Soluble
Result and discussion of complex formation:
Table no. 36 Result and discussion of complex formation:
S.NO Formulation Observation/PH Drug complexation
%
Taste
1 DRC-1
120mg=60mg
PH-9.2, Separation layer.
No complex formation - -
2 DRC-2
145mg=60mg
PH-5.2, no separation
complex
is formed
85.6% -
3 DRC-3
170mg=60mg
PH-3.5, no separation.
Complex is formed 99.2% Slightly
bitter
4 DRC-4
230mg=60mg
PH-3.68, no separation.
Complex is formed 99.38% Slightly
bitter
5 DRC-5
290mg=60mg
PH-3.85, no separation.
Complex is formed 99.82% Bland taste
6 DRC-6
290mg=60mg
PH-3.56, no separation.
Complex is formed 78.87% Bitter
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CALIBRATION CURVE:
Table No. 37 Calibration curve:
S NO. Concentration (µg) Absorbance
1 0 0
2 5 0.218
3 10 0.406
4 15 0.624
5 20 0.848
Figure No. 32 Calibration Curve
The ƛ max of etoricoxib was found to be 240 nm. The linear equation was y = 0.042 x
(x=concentration μg/ml). Different standard concentration and their absorbance were shown in
the table. Regression value of calibration curve is 0.999. A graph of Absorbance Vs
Concentration was found to be linear indicating its compliance with beers law.
y = 0.042x
R² = 0.9992
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Evaluation of compression parameters:
Weight variation Test:
Table No. 38 Weight variation Test:
S NO. Formulation Weight variation (mg)
(Mean±SEM)
1 EDI 1 403±0.96
2 EDI 2 402±0.71
3 EDI 3 403±0.32
4 ETI 1 404±0.55
5 ETI 2 401±0.39
6 ETI 3 402±0.62
All values are expressed as mean ± SEM for twenty determinations
Thickness:
Table no. 39 Thickness test:
S NO. Formulation Average weight of
tablet (mg)
Average thickness (mm)
Mean ± SEM
1 EDI 1 402 3.5 ± 0.09
2 EDI 2 401 3.7 ± 0.09
3 EDI 3 403 3.8 ± 0.09
4 ETI 1 403 3.9 ± 0.09
5 ETI 2 402 3.8 ± 0.09
6 ETI 3 402 3.9 ± 0.09
All values are expressed as mean ± SEM for three determinations
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Hardness:
Table No. 40 Hardness:
S NO. Formulation Average hardness (kg/cm2)
1 EDI 1 4.3
2 EDI 2 4.1
3 EDI 3 4.2
4 ETI 1 4.3
5 ETI 2 4.5
6 ETI 3 4.4
All values are expressed as mean ± SEM for three determinations
Friability:
Table No. 41 friability:
S NO. Formulation Friability
1 EDI 1 0.5%
2 EDI 2 0.7%
3 EDI 3 0.6%
4 ETI 1 0.8%
5 ETI 2 0.6%
6 ETI 3 0.9%
Pa
ge
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All values are expressed as mean ± SEM for three determinations
Drug content:
Table no. 42 Drug content:
S NO. Formulation Drug content uniformity (%)
1 EDI 1 91.20%
2 EDI 2 91.67%
3 EDI 3 93.80%
4 ETI 1 94.40%
5 ETI 2 96.23%
6 ETI 3 95.33%
Disintegration test:
Table no.43 Disintegration test:
S
NO.
Disintegration
test (sec)
EDI-1
Disintegration
test (sec)
EDI-2
Disintegration
test (sec)
EDI-3
Disintegration
test (sec)
ETI-1
Disintegration
test (sec)
ETI-2
Disintegration
test (sec)
ETI-3
1 52 53 48 44 39 45
2 55 53 45 43 39 48
3 52 55 47 45 38 47
4 58 54 50 44 35 50
52 ± 0.05 54± 0.03 48 ± 0.05 44 ± 0.02 37 ± 0.03 47 ± 0.03
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Figure 33 Comparative study of disintegration time in different formulations
Table no.44 Disintegration time:
S NO. Formulation Disintegration  time (sec)
1 EDI 1 58
2 EDI 2 54
3 EDI 3 50
4 ETI 1 44
5 ETI 2 35
6 ETI 3 47
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Figure no.34 Comparative study of different disintegrates
From the above data it was found that when crospovidone and croscarmellose sodium
was used in the formulation (ETI 2), the disintegration time found to be limited value of orally
disintegration tablet.
IN VITRO DISSOLUTION:
Dissolution profile of formulation:
The dissolution of formulation EDI 1, EDI 2, EDI 3, ETI 1, ETI 2, ETI 3 was carried out and the
% drug release
Table no. 45 Dissolution profile of formulation of ODT tablet
Time Dissolution
test
(con/time)
EDI-1 %
Dissolution
test
(con/time)
EDI-2 %
Dissolution
test
(con/time)
EDI-3 %
Dissolution
test
(con/time)
ETI-1 %
Dissolution
test
(con/time)
ETI-2 %
Dissolution
test
(con/time)
ETI-3 %
0 0 0 0 0 0 0
10 28.25 28.25 30.21 31.41 43.25 29.33
20 65.33 45.33 58.99 55.33 64.99 57.22
30 84.24 76.88 78.96 79.25 82.99 76.33
45 87.23 85.25 92.47 89.45 95.89 94.66
58 54 50 44
35
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Figure no. 35 Comparative study of formulations:
From the above data it was found that when crospovidone and croscarmellose sodium
was used in the formulation (ETI 2), the %drug release was found to be 95.89% at 45 mins time.
Comparison study of formulation tablet and marketed tablet:
Table no. 46 Comparison and study of formulation tablet marketed tablet
Time
Dissolution
test
(conc/time)
EDI 1
Dissolution
test
(conc/time)
EDI 2
Dissolution
test
(conc/time)
EDI 3
Dissolution
test
(conc/time)
ETI 1
Dissolution
test
(conc/time)
ETI 2
Dissolution
test
(conc/time)
ETI 3
Dissolution
test
(conc/time)
Marketed
sample
0 0 0 0 0 0 0 0
10 28.25 27.78 30.21 31.41 43.25 29.33 25.22
20 65.33 45.33 58.99 55.33 64.99 57.22 58.99
30 84.24 76.88 78.96 79.25 82.99 76.33 82.99
45 87.23 85.25 92.47 89.45 95.89 90.66 95.55
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Figure no. 36 formulation-marketed tablet
It is evident from the all formulations exhibit rapid and complete dissolution profile.
Formulation (ETI 2), exhibits the better dissolution profile than compared with marketed ODT
formulations.
Comparison study of marketed sample and ETI 2:
Table no. 47 Comparison study of marketed sample and ETI 2:
Time
ETI 2
(drug concentration)
Marketed tablet
(drug concentration)
0 0 0
10 43.25 25.22
20 64.99 58.99
30 82.99 82.99
45 95.89 95.55
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Figure No. 37 ETI 2-marketed tablet
Formulation (ETI 2), exhibits the better dissolution profile than compared with marketed ODT
formulations.
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STABILITY STUDIES ON SELECTED ODT TABLETS FORMULATION
Quality guidelines known as ICH guidelines have established a series of guidelines
acceptable to multiple countries for the drug approval process. (ICH Guidelines) It is a normal
practice to study the stability of pharmaceutical preparations at accelerated conditions of
temperature and humidity, the experimental findings which can be transformed into reliable shelf
life or expiry date by adopting certain assumptions or criterions (Cannorset al.1979). In
comparison to conventional preparations Pharmaceutical product represents number of unique
problems when quality and stability are considered. To ensure proper reproducibility, proper
control is essential an important part of quality control is to ensure the chemical stability of final
product during storage product. Present study is an attempt to study accelerated stability of ODT
tablets, these have been prepared using time tested pharmaceutical ingredient in optimum
concentration which includes etoricoxip ODT formulation.
METHODS
The present work on “Accelerated Stability study of Herbal Capsules” was undertaken to
standardize and study the stability profile of ODT tablets formulation. The study was done at
accelerated temperature and humidity conditions, i.e. accelerated stability study taking ICH
guidelines as reference. The ten tablets were randomly collected. Enough blisters in duplex were
kept in humidity chamber at 400 ±20 c and 70 ± 5% RH humidity. Required blisters were
withdrawn after one, two, three and six month in triplicate for analysis. The main ingredient of
ODT formulation initial sample 1, 2, 3 and 6 month of storage at accelerated conditions of
temperature and humidity. For evaluation different parameters were taken that were organoleptic
evaluation, identification tests, Average weight test, disintegration test, dissolution test. Samples
were tested at the time of their release of batch and after 1st, 2nd, 3rd and 6th month of storage.
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Summary:
The objective of present study is investigated formulation development and evaluated of
etoricoxib orally disintegration tablet by using ion exchange resin technique, in different
concentrations to enhance the disintegration profile. Etoricoxib is an anti-rheumatoid arthritis
drug, which is commonly prescribed for treatment of rheumatoid arthritis, osteoarthritis and
gout. It is a slightly soluble in water and it is cox-2 inhibitor. Etoricoxib has long biological half-
life (22hrs). In the present study, fast disintegrating tablets of etoricoxib ODT were prepared by
ion exchange resin complexation technique for better patient compliance and immediate action in
rheumatoid arthritis, and osteoarthritis. The tablets were prepared by using synthetic super-
disintegrants such as Cross povidone and croscarmellose sodium.
Preformulation studies:
FTIR showed no major degeneration the drug and excipients combination. The spectrum
peak point of the formulation were similar with that of pure etoricoxib, The pre-formulation
study carried out that angle of repose, bulk density, tapped density, compressibility, Hausner
ratio. The results were clearly shown.
Evaluation of Designed Formulations:
Post formulation studies
Physical characterization of all the lubricated blends were carried out and found to have
good flow properties. The tablets prepared with the plain polymer mixture combination were
found to have desired limits of hardness and thickness and complies to weight variation and
within the official limits of friability. The formulation EDI 1 and EDI 3 was added with
disintegrating agent such as crospovidone and croscarmellose sodium respectively. The result
was increases the disintegrating time. However the combination of disintegration formulation
EDI 2 was to reduce the disintegrating time. Then development study of taste improved process.
ETI 1 and ETI 3 each one sweetening agent added like that sucralose and neotame. But taste was
not compatible in this formulation. So combination sweeteners formulation ETI 2 is good taste of
Pa
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this formulation. In-vitro drug release for formulations EDI 1, EDI 2, EDI 3, ETI 1, ETI 2, and
ETI 3 is carried out. From this the % drug release was found to be better at formulation ETI 2
which is considered as optimized formulation. The drug release for formulation ETI 2 was found
to be 95.89% at the end of 45 mins. The prepared tablets were evaluated for Weight variation,
Hardness, Friability, Disintegration time, Drug content and in vitro dissolution tests. The results
were clearly shown. Accelerated Stability studies were also done for optimized formulation ETI
2 and the results were found satisfactory.
Conclusion:
The results of etoricoxib ODTs evaluation of different batches were done. The FT-IR
study shows that there was no interaction between the drug and the polymer. The weight
variation of 400mg tablets was found maximum up to ± 1.2 % RSD. Hardness was found to be
within 3.0 to 4.0 kg/cm2 which limit friability within 0.7% only. The evaluation results of ETI 2
batches were found to be satisfactory within limit and the disintegration time (35sec) was quite
good than synthetic mixture combination super disintegrants such as Crospovidone and
croscarmellose sodium. As the combination of super disintegratant concentration decrease with
same ratio the formulation ETI 2 gave 95.89% drug release at 45 mins time point,. The drug
Contents was found to be within limits and all tablets were passing the dispersion test. ODT
tablets of etoricoxib of optimized all batch were of satisfactory stability during 6 months of
accelerated stability studies.
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